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Abstract  
	
The focus of this master’s research was two-fold. First, the relationship between body 
mass index (BMI) and severity of coronary artery disease (CAD) was examined in 
patients undergoing diagnostic coronary angiography (CA) for suspected CAD in 
Newfoundland and Labrador, Canada. The primary outcomes were 1-year all-cause and 
cardiac specific mortality. Second, in patients with established CAD and undergoing 
percutaneous coronary intervention (PCI) the relationship between BMI and short-term 
adverse events including vascular and non-vascular (i.e., in-lab and post-procedural) 
complications was investigated. This thesis is presented in manuscript form and consists 
of four chapters with the first being an introduction and the fourth, final chapter being a 
discussion. The second chapter focuses on the relationship between BMI and 
angiographic severity of CAD, while the third chapter focuses on the impact of BMI on 
vascular and non-vascular complications in patients undergoing PCI. This research failed 
to detect an association of BMI levels with 1-year mortality in patients with suspected 
CAD after adjustment for potential confounding variables. Further, overweight and 
obesity were not independent correlates of short-term complications among patients with 
established CAD who had a PCI. 
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Chapter 1  Introduction and Overview 
	
1.1 Background and Rationale 
1.1.1	 Epidemiology	of	obesity	
According to the World Health Organization (WHO), obesity, defined as abnormal or 
excessive fat accumulation that may impair health [1], is reaching epidemic 
proportions worldwide.  Body mass index (BMI) is a method of classifying body 
weight according to health risk. It is calculated for the population aged 18 and over, 
excluding pregnant females and persons less than 3 feet (0.914 metres) tall or greater 
than 6 feet 11 inches (2.108 metres). [2] BMI is calculated as weight in kilograms 
divided by height in metres squared (kg/m2). The BMI index is categorized in the 
following way: under 18.5 (underweight); BMI 18.5 to 24.9 (normal weight); BMI 
25.0 to 29.9 (overweight); BMI 30.0 to 34.9 (obese-Class I); BMI 35.0 to 39.9 (obese-
Class II); BMI 40 or greater (obese - Class III). [1-3] 
 
In 2014, approximately 13% of adults 18 years of age and older, worldwide were 
obese (i.e., BMI ≥ 30kg/m2) and 39% were overweight (i.e., 25.0 to 29.9 kg/m2). Since 
the 1980s obesity has more than doubled. [1] Canada is no exception to this increasing 
trend among adults. The prevalence of obesity in Canada increased from 6.1% to 
18.3%, (i.e., 200%) between 1985 and 2011, equating to more than 4.8 million adults 
.[4] Continued increases have been projected for all Canadian provinces up to 2019. 
[4] Newfoundland and Labrador (NL) has the highest rate of obesity in the country and 
2	
	
it is estimated that 71% of the province’s population will be either overweight or obese 
by 2019. [4]  
Alarmingly, the prevalence has increased substantially in children and adolescents in 
developed countries: 23.8% of boys and 22.6% of girls were overweight or obese. In 
developing countries, the prevalence of overweight and obesity has also increased in 
the last few decades in children and adolescents from 8.1% to 12.9% in boys and from 
8.4% to 13.4 % in girls. [5] 
1.1.2	 Obesity	and	health	risk	
People are becoming overweight and obese at a younger age and are exposed to 
cardiovascular risk factors such as hypertension, diabetes mellitus, hyperlipidemia and 
smoking [6] and are at greater risk to develop coronary artery disease (CAD). [7]  
Weight loss of 5-10% has been associated with improvement in pre-existing 
cardiovascular risk factors including hypertension, diabetes and dyslipidemia, 
improvement in clinical events, and outcome (i.e., mortality). [8-13]  
 
According to WHO [1] and Health Canada guidelines [2], health risk levels are 
associated with each of the following BMI categories: normal weight = least health 
risk; underweight and overweight = increased health risk; obese class I = high health 
risk; obese class II = very high health risk; obese class III = extremely high health risk. 
 
Obesity is an independent risk factor for cardiovascular disease [14-18], and patients 
with a high BMI are considered to be at high risk for cardiovascular disorders. It has 
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been associated with (1) advanced cardiovascular disease such as acute coronary 
syndrome (ACS) requiring procedures such as percutaneous coronary intervention 
(PCI) and coronary artery bypass grafting (CABG), (2) reduction in life expectancy 
[19], and (3) a higher mortality rate [16, 20-21].  Because of the high prevalence of 
CAD, overweight and obese patients more frequently undergo revascularization 
procedures such as PCI and CABG.  Population-based registries and databases have 
reported the prevalence of overweight and obesity to be as high as 70% to 80% among 
patients undergoing revascularization procedures. [22-25] 
1.1.3	 Obesity	paradox	
Cardiovascular disease with CAD is by far the most important cause of excess deaths 
in obese patients. [26] In the general population, overweight and obesity are associated 
with increased risk of cardiovascular disease and all-cause-mortality. [27-28]  In the 
Prospective Studies Collaboration, based on 66,552 deaths among 894,576 participants 
in 57 prospective studies, the observed reduction in median survival was 0-2 years in 
overweight individuals, 2-4 years in obese individuals, and 8-10 years in very obese 
individuals. [29]  
 
Research examining the number of deaths in Canada attributable to obesity found that 
almost 1 in 10 premature deaths among those 20-64 years of age were attributed to 
overweight and obesity. The proportion of all deaths among adults 20-64 years of age 
that could be attributed to overweight and obesity increased from 5.1% in 1985 to 
9.3% in 2000. [30] A Canadian study involving 11,326 participants who were followed 
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for 12 years reported that compared with those in the normal weight category, even 
after adjustment for key sociodemographic factors and health behaviors, those in the 
underweight, class II or class III obesity categories had a significantly increased risk of 
all-cause mortality. In contrast, people who were overweight but not obese had a 
significantly lower risk than normal weight population. There was no significant 
difference in risk of mortality between obesity class I and normal weight respondents. 
[31] Higher mortality in the highest weight category and higher mortality in the lowest 
weight categories compared with those who are of normal weight has been described 
as a J- or U-shaped mortality curve. [32-33]  
Although obesity is associated with higher overall mortality risk in the general 
population, several studies have suggested that obesity confers a survival advantage in 
a number of diseases. The phenomenon was first described in 2002 by Gruberg et al. 
[22] Consecutive patients undergoing PCI (N= 9,633) were categorized in groups: 
BMI < 24.9 kg/m2 (n=1,923), BMI = 25-30 kg/m2 (n=4,813), and BMI > 30 kg/m2 
(n=2,897). Normal weight patients had a higher incidence of major in-hospital 
complications, including cardiac death (1.0% vs. 0.7% vs. 0.4%; p = 0.001), than 
overweight or obese patients. At 1 year, mortality was significantly higher in normal 
BMI patients compared to overweight or obese patients (10.6% vs. 5.7% vs. 4.9%; p < 
0.0001) and for cardiac mortality (4.8% vs. 3.3% vs. 2.5%; p < 0.0001), whereas rates 
of myocardial infarction and revascularization were similar despite a better baseline 
clinical profile of normal weight patients. 
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This unexpected and controversial finding, termed “obesity paradox”, has been 
reported in patients with diabetes [34], end-stage renal disease [35], hypertension [36], 
heart failure [37], CAD [36, 38-40], CABG [38-41], PCI [38-40], stroke [42], 
peripheral vascular disease [43] and chronic obstructive pulmonary disease [44]. The 
mechanisms leading to this phenomenon are unclear. 
Four meta-analyses focused on the CAD patient population have reported that being 
overweight or obese (BMI ≥ 25kg/m2) is associated with greater survival in CAD 
patients, whereas a normal BMI confers higher all-cause and cardiovascular mortality. 
A large meta-analysis performed by Romero-Corral et al. in 2006 which included 
250,152 patients with established CAD and a mean follow-up of 3.8 years reported 
that overweight and obese CAD patients have a lower risk for total and cardiovascular 
(CV) mortality after revascularization compared with underweight and normal-weight 
CAD patients. However, in patients with a BMI ≥35 kg/m2, there was an excess risk 
for CV mortality without any increase in total mortality. [39] This meta-analysis 
demonstrated that moderately obese individuals (BMI 30-35 kg/m2) and those who 
were severely obese (BMI ≥35 kg/m2) do not have a significantly greater risk for total 
mortality (RR, 0.93, 95% CI, 0.85-1.03 and RR, 1.10, 95% CI, 0.87-1.41, 
respectively). However, although moderately obese patients had no increase in 
cardiovascular mortality (RR, 0.97, 95% CI, 0.82-1.15) compared with the normal-
weight group, those with severe obesity had a greater risk, (RR, 1.88, 95% CI, 1.05-
3.34). In addition, CV mortality was worse among the severely obese. In 2008, 
Oreopoulos et al. [38] compared the short- and long-term mortality in a large cohort of 
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patients with established CAD undergoing PCI and CABG. The findings suggest that 
the in-hospital and long-term mortality rates were similar or lower in obese patients 
compared to normal weight patients irrespective of initial treatment strategy. Patients 
with mild or moderate obesity treated with either revascularization or medical 
management were at lower adjusted risk of mortality when compared with patients 
with a normal BMI. [38] This meta-analysis included articles published 20 years ago, 
in the year 1996. A meta-analysis by Sharma et al. [45] in 2014 which included 36 
studies with a mean follow-up period of 1.7 years reported higher total (RR, 2.59, 95% 
CI, 2.09-3.21) and CV (RR, 2.67, 95% CI, 1.63-4.39) mortality rates among the 
underweight patients. The risk of CV mortality was lowest among the overweight 
patients (RR, 0.81, 95% CI 0.68-0.95). A more recent meta-analysis published by 
Bundhan et al. in 2015 comprised of 22 studies conducted from 2000 to 2015 consisted 
of 242,377 patients  (73,143 normal weight, 103,608 overweight, and 65,626 obese) 
undergoing PCI. They reported that in-hospital (RR, 0.62, 95% CI 0.55-0.71; RR, 
0.57, 95% CI 0.52-0.63), 12 months (RR, 0.62, 95% CI 0.55-0.71; RR, 0.57, 95% CI 
0.52-0.63)  and ≥ 1-year (long-term) (RR, 0.62, 95% CI 0.55-0.71; RR, 0.57, 95% CI 
0.52-0.63) mortality risks were significantly lower in the overweight and obese groups 
respectively. [46]  
Although meta-analytic findings have reported improved clinical outcomes in 
overweight and obese patients treated for cardiovascular diseases compared to normal 
weight patients, suggesting a paradoxical survival benefit; other studies have shown an 
absence of this phenomenon. Uncertainty exists about the relationship between BMI 
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and mortality after PCI. For example, in a study of patients treated with drug-eluting 
stents in a routine clinical practice similar rates of all-cause death, and major adverse 
cardiac and cerebrovascular events defined as the composite of cardiac and noncardiac 
death, myocardial infarction, and stroke were observed between normal weight 
patients compared to overweight and obese individuals. [47] Akin et al. concluded that 
there was no evidence of an obesity paradox in a routine clinical practice of patients 
undergoing PCI with drug-eluting stents. In another German network registry analysis 
of 890 consecutive patients presenting with ST-segment elevation myocardial 
infarction (STEMI) including cardiogenic shock, normal weight patients and obese 
patients had similar rates of all-cause mortality even after risk-adjustment for baseline 
characteristics suggesting no evidence of an obesity paradox in the STEMI population 
including patients with cardiogenic shock. [48]  
1.1.4	 The	Relationship	between	BMI	and	severity	of	CAD	in	suspected,	but	not	
yet	confirmed	patients	with	CAD.	
The obesity paradox has also been reported in patients with suspected, but not yet 
confirmed, CAD. Coronary angiography (CA) can be used to in clinical practice and 
research to quantify CAD severity. [49] Historically CAD has been categorized as 
single, double, triple-vessel, and left main disease, with luminal stenosis of either 
≥50% (left main) or ≥70% (other major epicardial vessels) used to define significance. 
[50] However, the perception that stratification of patients with risk level variation was 
limited, lead to the development of more meaningful scoring systems to determine the 
severity of CAD and prognosis. [51-53]  
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One such scoring system was developed by Dash et al. [52] The Duke Jeopardy Score 
(DJS) was used to predict mortality in patients undergoing CA for suspected but 
unconfirmed CAD.  Dash et al. [52] developed the DJS, a prognostic tool predictive of 
1-year mortality in patients with CAD, which was validated by Califf et al. [53] in 
1985. The coronary tree is divided into 6 segments: the left anterior coronary artery 
(LAD), diagonal branches of the LAD, septal perforating branches, circumflex 
coronary artery, obtuse marginal branches, and posterior descending coronary artery. 
All segments with ≥75% stenosis, or ≥ 50% left main stenosis, are considered to be at 
risk. Each such segment is assigned 2 points. The maximum possible number of points 
is 12. A score from 0 to 12 is assigned to each CA based on the number of segments 
involved. In the study by Califf et al. [53] the authors reported an association between 
the DJS and 5-year survival. The 5-year survival was 97% in patients with a DJS of 2 
and 95%, 85%, 78%, 75% and 56% for patients with DJS of 4, 6, 8, 10, and 12, 
respectively. [53] The prognostic value of the DJS was greater than the number of 
diseased vessels. Thus, patients with a score of ≥8 represented a different and more 
anatomically high-risk population than the multivessel CAD population, leading to a 
different relationship between the cardiovascular risk factors (i.e., diabetes, male sex, 
family history of CAD, hypertension, dyslipidemia, smoking and obesity) and CAD 
severity. 
 The DJS is the validated scoring system [52-55] used by APPROACH-NL to estimate 
the amount of myocardium at risk and was therefore used in the current study. It is a 
validate prognostication tool and an index of CAD burden predictive of 1-year 
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mortality in patients treated medically or with PCI. Detailed CA data are automatically 
populated from the Coronary Artery Reporting and Archiving Tool (CARAT), a 
graphic recording and communication application. [56] A PDF file is created 
containing the anatomy of the coronary arteries according to the DJS and becomes part 
of each patient’s medical record.   
As mentioned previously, obesity is an accepted risk factor for CAD; therefore, it 
could be assumed that obese patients have poorer outcomes than non-obese patients. 
[57] However, a number of studies have reported findings that contradict this 
supposition about the relationship between BMI and mortality in patients undergoing 
CA for suspected CAD. Studies that have focused on BMI and angiographically 
demonstrated CAD have found that obese patients tend to have less severe and 
extensive CAD than non-obese patients. Very few studies have examined the 
association of body mass index (BMI) and CAD in patients undergoing CA. In a study 
by Rubinshtein et al. [58] obese patients referred for CA were younger and had a lower 
prevalence of left main disease. Multivariate regression analysis showed advancing 
age, male gender, diabetes, and hyperlipidemia were independent predictors of high-
risk anatomy, whereas obesity remained a significant negative independent predictor 
(p =0.02).  Late mortally (30 to 36 months) was not different between obese (6.9%) 
and non-obese (8.2%) patients but was significantly higher in patients with high-risk 
coronary anatomy (12.4%) than in those without high-risk coronary anatomy (5.6%, p 
= 0.003).  Niraj et al. [59] also found that obese patients from the U.S. (N=770) 
referred for CA were younger and had a lower burden for CAD; however, the authors 
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did not find obesity to be a significant predictor for severity of CAD after adjustment 
for confounders and suggested that younger age may have influenced the obesity 
paradox observed in their study. BMI was not a significant predictor of more severe 
coronary anatomy. In a 2011 study examining the influence of BMI on extent of 
coronary atherosclerosis and cardiac events in a cohort of patients at risk of CAD, 
Rossi et al. [60] found that BMI was not significantly associated with extent of 
coronary atherosclerosis and mortality confirming the earlier findings of others [56-
57]. Parsa and Jahanshahi [61] also reported an inverse relationship between BMI and 
severity of CAD in a cross-sectional, prospective study of 414 patients with suspected 
CAD. No Canadian studies were identified that examined the relationship between 
BMI and severity of CAD in patients undergoing CA for suspected CAD.  
1.1.4.1	Summary	of	gaps	in	the	literature	
Cardiac catheterization for coronary angiography is an invasive procedure with 
inherent risks. Several authors have suggested that, paradoxically, obese patients have 
a lower CAD burden (measured by the Duke Jeopardy Score [DJS]) and lower 
prevalence of high-risk coronary anatomy (significant left main or triple vessel 
disease) compared to non-obese patents despite a higher prevalence of diabetes, 
hypertension, and dyslipidemia. [59, 62-63]  
The relationship between obesity and severity and extent of CAD remains 
controversial. The clinical implication of whether or not obesity is directly related to 
CAD prognosis is still subject to debate. Although obesity is clearly a risk factor for 
developing CAD, obesity itself may not necessarily expose patients undergoing 
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coronary CA to greater risk. A greater understanding of why obesity is associated with 
less angiographic CAD is necessary to prevent potentially unnecessary cardiac 
catheterizations from being done in this patient population. No Canadian studies were 
identified that examined the relationship between BMI and severity of CA in patients 
undergoing CA for suspected CAD. To the best of our knowledge this study which 
focused on the NL adult patient population will be the first Canadian study to 
investigate this issue. 
1.1.5	 The	Relationship	between	BMI	and	short-term	outcomes	(i.e.,	vascular	
and	non-vascular	in-lab/post-procedural)	in	patients	with	established	
CAD	undergoing	PCI 
Studies that have investigated the relationship between BMI and clinical outcome 
following PCI have reported contradictory findings. [22-25, 59, 64-77] Numerous 
studies and large meta-analyses have demonstrated an “obesity paradox” in which 
lean patients with established cardiovascular disease (CVD) have a worse clinical 
prognosis than do their more overweight/obese counterparts with the same CVD, 
including coronary heart disease (CHD). However, several studies suggest that obese 
patients within the higher classes of obesity do not have more favorable outcome. In a 
large systematic review of over 250,000 CHD patients in 40 cohort studies followed 
for 3.8 years, Romero-Corral et al. reported that overweight and obese CHD patients 
had a lower cardiovascular and total mortality compared to underweight and normal 
weight patients; however, patients with class II obesity (BMI >35 kg/m2) were at 
greater risk of cardiovascular mortality but still no increase in total mortality. Das et al. 
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reported a U-shaped in hospital mortality curve in a very large cohort with ST-segment 
myocardial infarction. The normal BMI group had the highest unadjusted in hospital 
mortality. However, the patients with class III obesity (BMI ≥40 kg/m2) had increased 
mortality in both unadjusted and adjusted models compared with the referent group 
(class I obesity).  In a 2013 study by Angeräs et al. [78] of over 60,000 patients 
referred for CA, compared to the lean referent group (BMI 21.0-23.5 kg/m2), the 
highest mortality occurred in the underweight group (BMI < 18.5 kg/m2), the lowest 
mortality occurred in the modest overweight group (BMI 26.5-28.0 kg/m2), whereas 
mortality remained lower for obesity up to 35 kg/m2, and then increased.  
The findings of Azimi et al. [79] from a large cohort of 35,573 patients with 
established CHD, who were followed for 11 years (median 3.2 years) demonstrated 
that the highest mortality occurred in underweight (BMI < 18.5 kg/m2), followed by 
the class III group (BMI ≥ 40kg/m2). Increased mortality risk was observed among the 
low normal BMI group (BMI < 18.5-23.0 kg/m2), whereas the lowest mortality was in 
the pre-obese group (BMI 27.5-30 kg/m2), followed by the mild overweight (BMI 25-
27.5 kg/m2). The authors suggest that the relationship between BMI and mortality in 
CHD might represent an “overweight paradox” rather than an “obesity paradox”.  In a 
2013 systematic review and meta-analysis of 97 studies of more than 2.88 million 
individuals in the general population,  Flegal et al. [21] found that the lowest mortality  
occurred in overweight (BMI 25-30 kg/m2), followed by mild or class I obesity(BMI 
30-35 kg/m2). These findings lend support to the potential protective relationship of 
overweight in both the general population and in cohorts of patients with CHD.    
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Although the preceding studies and meta-analyses have focused primarily on mortality 
as a clinical outcome in patients with established CAD, many studies have also 
examined the association between BMI and clinical outcomes after PCI including in-
hospital mortality, bleeding events (e.g., access site bleeding), vascular complications 
(e.g., pseudoaneurysm, arteriovenous fistula, vascular occlusion, retroperitoneal 
bleeding),  stent thrombosis, major adverse cardiovascular (e.g., stroke) and cardiac 
events (e.g., myocardial infarction). As mentioned earlier, Gruberg et al. [22] first 
described an obesity paradox in 2002 in a study of consecutive patients undergoing 
PCI (N= 9,633) were categorized in groups: BMI < 24.9 kg/m2 (n=1,923), BMI = 25-
30 kg/m2 (n=4,813), and BMI > 30 kg/m2 (n=2,897). Normal weight patients had a 
higher incidence of major in-hospital complications, including cardiac death (1.0% vs. 
0.7% vs. 0.4%; p = 0.001), than overweight or obese patients. At 1 year, normal BMI 
patients compared to overweight or obese patients	mortality had significantly higher 
rates of all-cause mortality (10.6% vs. 5.7% vs. 4.9%; p < 0.0001) and cardiac 
mortality (4.8% vs. 3.3% vs. 2.5%; p < 0.0001), whereas rates of myocardial infarction 
and revascularization were similar despite a better baseline clinical profile of normal 
weight patients.  
Findings from other studies also suggest that obesity may be associated with better 
short-term outcome (e.g., decreased risk of death, bleeding complications, vascular 
complications such as arteriovenous fistula, pseudoaneurysm, hematoma) in patients 
undergoing PCI [23-25, 64-66, 68, 71, 74, 77, 80]. For example, Mehta et al. studied 
2,325 patients with acute myocardial infarction who received primary PCI and 
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reported that although obese patients (those with a BMI ≥ 30 kg/m2) had more 
cardiovascular risk factors at baseline, they had fewer groin bleeds, shorter hospital 
stays, and fewer deaths in the hospital and at 12 months than did patients with a 
normal BMI. The authors suggested that the difference may have been due to the fact 
that obese patients were a mean of 6 years younger than the patients with normal BMI 
or because obesity is related to impaired fibrinolysis and increased platelet 
aggregation. [64] Gurm et al. [66] pooled data from 4 randomized controlled trials of 
platelet glycoprotein IIb/IIIa inhibitors in patients who underwent PCI and concluded 
that increased BMI was associated with a decreased risk of myocardial infarction, 
death, need for urgent revascularization, and hemorrhagic complications.  The risk of 
major or minor bleeding and transfusion requirement was highest in lean patients 
(BMI < 18.5 kg/m2) and lowest in obese patients (BMI ≥ 30 kg/m2). Delhaye et al. [65] 
examined the role of BMI in records of 16,783 patients who underwent PCI. The 
patients were grouped according to six BMI categories: underweight (BMI, < 18.5), 
normal weight (BMI, 18.5-24.9), overweight (BMI, 25-29.9), class I obesity (BMI, 30-
34.9), class II obesity (BMI, 35-39.9), class III obesity (BMI, ≥40). The incidence of 
major bleeding varied significantly (p<0.001) among BMI groups: underweight 
(5.6%), normal weight (2.5%), overweight (1.9%), class I obese (1.6%), class II 
obesity(2.1%), class III obesity (1.9%). Compared with normal weight patients, the 
risk of major bleeding was higher in underweight patients (OR, 2.29 [95% CI, 1.56-
3.38]) and lower in Class I obese patients (OR, 0.65 [95% CI, 0.47-0.90]).  In a 
retrospective review of 5,234 patients undergoing PCI, Cox et al. [68] reported that the 
rates of vascular complications was highest in extremely thin and morbidly obese 
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patients and lowest in moderately obese patients. In a study by Das et al. [74], after 
multivariate adjustment, extreme obesity (i.e., class III) was associated with increased 
in-hospital mortality (OR, 1.64, 95% CI, 1.32-2.03). Normal weight was associated 
with increased major bleeding (OR, 1.18, 95% CI, 1.08-1.30), while class III obesity 
was not (OR, 1.09, 95% CI, 0.94-1.26). Powell et al. found that compared to obese 
patients, underweight patients had higher rates of femoral bleeding, hematoma, and 
blood loss that required transfusion. [80]  
In contrast to the observed overweight paradox and obesity paradox, recent studies 
found no association between BMI and 1-year mortality [72] following PCI or BMI 
and short-term complications [47-48]. In a 2010 study by Ndrepepa et al. [72] that 
investigated the impact of BMI on clinical outcome after adjustment for other 
cardiovascular risk factors in 9,146 patients with acute coronary syndromes (ACS) 
who underwent CA and PCI, BMI was not an independent correlate of 1-year 
mortality [HR, 1.25, 95% CI, 0.94-1.64, p = 0.127 for the 1st vs 4th BMI quartile]. In a 
2012 study Akin et al. [47] compared the clinical outcomes among unselected patients 
stratified by BMI from the prospective multicenter German drug-eluting stent registry 
who underwent PCI. In-hospital and 1-year outcomes including the rate of major 
adverse cardiac and cerebrovascular events (MACCE) defined as a composite of death, 
myocardial infarction, and stroke and target vessel revascularization were examined. 
Baseline clinical characteristics were more severe for overweight and obese patients. 
After risk-adjustment, 1-year follow-up comparison between groups revealed similar 
rates of all-cause death (3.3% vs. 2.4% vs. 2.4%, p = 0.17), MACCE (7.1% vs. 5.6% 
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vs. 5.5%, p = 0.09) and target vessel revascularization in survivors (10.9% vs. 11.7% 
vs. 11.6%, p = 0.56) in normal weigh patients compared to overweight or obese 
individuals. No evidence of an obesity paradox was observed.  In a 2015 study of 890 
consecutive patients admitted and treated for STEMI including cardiogenic shock and 
cardiopulmonary resuscitation, Akin et al. [48] found that after risk-adjustment, 1-year 
follow-up comparison between groups revealed similar rates of all-cause death (9.13% 
vs. 8.3% vs. 6.2%, p = 0.50), MACCE (15.1% vs. 13.4% vs. 10.2%, p = 0.53) and 
target vessel revascularization in survivors (7.0% vs. 5.0% vs. 4.0%, p = 0.47) in 
normal weigh patients compared to overweight or obese individuals. Similar to the 
authors’ study in 2012, the findings did not support the presence of an obesity paradox 
The authors suggested that the obesity paradox reported by others might be related to 
bias that could not be adjusted for using statistical methods. 
1.1.5.1	Summary	of	gaps	in	the	literature 
A significant number of studies have investigated the impact of obesity on the clinical 
outcomes of patients undergoing PCI since the obesity paradox phenomenon was first 
described by Gruberg et al. in 2002. [22], but it remains a controversial issue. Many of 
these studies have suggested the existence of an obesity paradox, i.e., that despite 
being associated with increased risk of coronary artery disease, increased BMI predicts 
more favorable outcome after coronary revascularization.  Other studies have shown 
contradictory effects of obesity on outcome after PCI. More recently researchers have 
suggested the existence of an overweight paradox rather than an obesity paradox. The 
issue of the existence of an obesity paradox remains controversial. A small number of 
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studies in recent years have found no support for the existence of a protective effect of 
overweight or obesity on clinical outcome following PCI. Given the global obesity 
trends and the association of obesity and CAD, the proportion of patients who undergo 
coronary revascularization who are obese is likely to increase. More research is 
required to address knowledge gaps and the contradictory findings that currently exist 
in the research literature. 
1.2 Purpose 
There is a paucity of data on the prevalence of obesity in patients undergoing CA 
and/or PCI in the province of NL and differences among BMI groups on demographic, 
clinical, and procedural findings. As well, the relationship between BMI and 
angiographically determined CAD severity requires further research to determine if 
obese patients are less likely to have severe CAD than non-obese patients. Further, the 
relationship between short-term clinical outcomes (vascular complications, non-
vascular in-lab and post-procedural complications occurring within 48 hours) and BMI 
has not been examined. 
The current study was performed for the following purposes (1) to examine the 
relationship between BMI and severity of CAD and its impact on mortality (i.e., 1-year 
all-cause and cardiac specific mortality) in the NL patient population referred for CA 
to a single tertiary care centre in the province, and (2) to determine the effect, if any, of 
BMI on short-term outcomes (24-48 hours) in patients who had a PCI. 
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1.3 Area of Investigation 
Newfoundland and Labrador (NL) is a Canadian province situated on the eastern side 
of the country with a population of approximately 528,000. [81] The General Hospital, 
located at the Health Science Centre, in St. John’s is the only diagnostic cardiac 
catheterization centre in the province.  
Detailed demographic, clinical, and procedural data on all patients undergoing 
diagnostic cardiac catheterization, percutaneous coronary intervention, or CABG is 
collected by specially trained cardiac care nurses.  Sociodemographic and clinical data 
such as age, sex, weight, height, current smoking status, family history of premature 
CAD, co-morbid conditions, medications, in-lab and post-procedural data, etc. is 
collected and entered into the Alberta Provincial Project for Outcome Assessment in 
Coronary Heart Disease –NL database. Data are collected for a 24-48 hour period (i.e., 
24 hours for out-patients and 48 hours for in-patients). 
1.4 Significance of the Study 
Since the relationships between BMI and severity of CAD and BMI and clinical 
outcome following PCI remain poorly understood, two studies were conducted to 
address gaps in the research literature and advance current knowledge in this field. The 
first study specifically examined the relationship between BMI and severity of CAD in 
patients with suspected, but unconfirmed CAD, referred for CA in one Canadian 
province. The primary outcome was one-year all-cause and cardiac-specific mortality. 
The second study explored the relationship between BMI and short-term complications 
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in patients with established CAD undergoing PCI. The primary outcomes were 
vascular and in-lab/ post-procedural adverse events.  
1.5 Program of Research for Thesis 
This section is intended to provide the reader with details on this student’s personal 
contribution to the program of research and a clear distinction between individual and 
team effort.  
After completing Medical School in 2013, I worked on a small research project in my 
post-graduate year 1 of internal medicine under the supervision of Dr. Neil Pearce, an 
interventional cardiologist and director of APPROACH –NL at Eastern Health. My 
research initially focused on the impact of body mass index on in-hospital 
complications in patients undergoing diagnostic cardiac catheterization and/or 
percutaneous coronary intervention from 2006 to 2010 in NL. I was the principal 
investigator on an application to the Health Research Ethics Authority (HREA) and 
responsible for the development of the proposal for ethics review and data analysis. 
After obtaining permission from Ms. Cathy Burke, Regional Director, Cardiac Care 
Program at Eastern Health to access de-identified data, I worked with Jennifer 
Matthews, Project Coordinator of APPROACH-NL to access the necessary data to 
conduct my data analysis. I subsequently presented my research findings as an oral 
presentation at Internal Medicine Resident Research Days in May 2014.  
Prior to this I enrolled as a graduate student in the Clinical Epidemiology program at 
Memorial University in the fall of 2013 under the co-supervision of Dr. Laurie Twells 
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and Dr. Neil Pearce. As part of my thesis work I was to continue with my resident 
research topic i.e., the impact of body mass index on in-hospital complications in 
patients undergoing diagnostic cardiac catheterization and/or percutaneous coronary 
intervention but to expand on the number of years (i.e., 2006 to 2013). An amendment 
to my original application to the HREA was made requesting ethical approval to obtain 
additional years of de-identified data.  I analyzed the additional data and provided an 
update at Internal Medicine Resident Research Days, Memorial University in my 
second year of residency.  
In addition to this work, in August 2015 I was to investigate the issue of BMI and 
severity of coronary artery disease in patients undergoing CA. This required obtaining 
additional data, more specifically, Duke Jeopardy Scores and 1-year all-cause and 
cardiac-specific mortality data on all patients undergoing CA from 2006 to 2013. 
Ethical approval was given to obtain this data and to conduct a secondary analysis of 
the de-identified APPROACH-NL data.  The findings were presented at Internal 
Medicine Resident Research Days, Memorial University in my third year of residency.  
After completion of my data analysis I was primarily responsible for drafting two 
papers as part of my thesis. I am first author on both manuscripts - one has been 
published and the other is under review. The preparation of the manuscripts has been a 
team effort, but as part of that effort I have been involved with the study concept and 
design, statistical analysis and interpretation of the data, drafting of the manuscripts, 
and critical revision of the manuscripts for important intellectual content.  
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1.6 Research Objectives 
The specific research objectives guiding this master’s work were as follows: 
1. To identify all patients who underwent a diagnostic coronary angiography 
(CA) from May 1st, 2006 to December 31st, 2013 enrolled in the Alberta 
Provincial Project for Outcome Assessment in Coronary Heart Disease - 
Newfoundland and Labrador (APPROACH - NL) database. 
2. To examine the relationship between BMI and severity of CAD and its impact 
on short-term outcomes (i.e. 1 year all-cause and cardiac-specific mortality) in 
in the NL patient population referred for CA for suspected CAD at a single 
tertiary care centre in the province. 
3. To identify all patients who underwent PCI from May 1st 2006 to December 
31st, 2013 enrolled in the APPROACH - NL database. 
4. To investigate the effect of BMI on short-term outcomes (vascular 
complications, in-lab non-vascular complications, post procedural adverse 
events occurring within 24 hours (out-patients) to 48 hours (in-hospital 
patients)). 
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2.1 Abstract  
Objective: To examine the relationship between body mass index [BMI (kg/m2)] and 
angiographic severity of coronary artery disease (CAD). 
Background:  Obesity is associated with increased risk of cardiovascular disease and 
may be associated with more severe CAD; however, the relationship between BMI and 
severity of CAD is uncertain and remains a controversial topic. 
Methods: 8,079 patients undergoing coronary angiography (CA) for suspected CAD 
were identified in the APPROACH Newfoundland and Labrador (NL) database. Duke 
Jeopardy Score (DJS), a prognostic tool predictive of 1-year mortality in CAD, was 
assigned to angiographic data. Patients were grouped into 3 BMI categories: normal 
(18.5-24.9 kg/m2), overweight (25.0-29.9 kg/m2), and obese (≥ 30 kg/m2) and 
multivariable adjusted hazard ratios for 1-year all-cause and cardiac-specific mortality 
calculated. 
Results: 84% of the cohort was overweight or obese. Cardiac risk factor prevalence 
significantly increased with increasing BMI. BMI was inversely proportional to DJS, 
indicative of less severe CAD in patients with higher BMI. 199 deaths (2.5%) including 
99 cardiac specific occurred with a significantly higher proportion of deaths occurring in 
normal weight patients despite more favourable baseline characteristics (p < 0.001). 
Mortality tended to rise with incremental increases in DJS. 
Conclusions: Obesity was associated with less severe CAD as evidenced by CA, 
suggesting obese patients are more likely to be referred early for CA based on the 
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prevalence of cardiovascular risk factors. This study failed to detect an association of 
BMI with 1-year mortality after adjustment for potential confounding variables.  
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2.2  Introduction 
Overweight and obesity are defined as “abnormal or excessive fat accumulation that may 
impair health”. [1] In 2014, approximately 39% of adults worldwide were overweight and 
13% were obese. Obesity has more than doubled since the 1980s. [1] Between 1985 and 
2011, the prevalence of obesity in Canada increased 200% from 6.1% to 18.3% equating 
to more than 4.8 million adults, with continued increases expected. [2] Newfoundland and 
Labrador (NL), a Canadian province, has the highest rate of obesity in the country and it 
is estimated that 71% of the province’s population will be either overweight or obese by 
2019. [2]  
Obesity is an independent risk factor for cardiovascular disease [3-7], and is associated 
with advanced cardiovascular disease requiring procedures such as percutaneous coronary 
intervention (PCI), reduction in life expectancy [8], and a higher mortality rate [5, 9, 10]. 
Weight loss has been associated with improvement in pre-existing cardiovascular risk 
factors including hypertension, diabetes and dyslipidemia and mortality. [11-14] Despite 
these findings, other studies have reported improved clinical outcomes in overweight and 
obese patients treated for cardiovascular diseases compared to normal weight patients, 
suggesting a paradoxical survival benefit. This “reverse epidemiology” or counter-
intuitive outcome has been reported in patients with diabetes [15], end-stage renal disease 
[16], hypertension [17] and multiple other conditions traditionally associated with poorer 
outcomes [18-25]. The mechanisms leading to this phenomenon, termed “obesity 
paradox”, are unclear. 
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The quantification of CAD severity for clinical practice and research purposes can be 
captured using coronary angiography (CA). [26] Historically CAD has been categorized 
as single, double, triple-vessel, and left main disease, with luminal stenosis of either 
≥50% (left main) or ≥70% (other major epicardial vessels) used to define significance. 
[27] However, stratification of patients with risk level variation was perceived to be 
limited using this approach. As a result, more meaningful scoring systems to determine 
the severity of CAD and prognosis were developed. [28-30]  
Very few studies have examined the association of body mass index (BMI) and CAD in 
patients undergoing CA. In a study by Rubinshtein et al. [31] patients with obesity 
referred for CA were younger and had a lower prevalence of left main disease. Niraj et al. 
[32] also found that obese patients referred for CA were younger and had a lower burden 
for CAD; however, the authors did not find obesity to be a significant predictor for 
severity of CAD after adjustment for confounders suggesting that younger age may 
influence the obesity paradox. Parsa and Jahanshahi [33] also reported an inverse 
relationship between BMI and severity of CAD in a cross-sectional, prospective study of 
414 patients with suspected CAD.  
Obesity is an accepted risk factor for CAD; therefore, it may be assumed that obese 
patients have poorer outcomes than non-obese patients. [34] However, a number of 
studies report findings that contradict this supposition about the relationship between 
BMI and mortality in patients undergoing CA for suspected CAD.  In a 2011 study 
examining the influence of BMI on extent of coronary atherosclerosis and cardiac events 
in a cohort of patients at risk of CAD, Rossi et al. [35] found that BMI was not 
40	
	
significantly associated with extent of coronary atherosclerosis and mortality confirming 
the findings of others [31,36, 37]. 
The aim of the current study was to examine the relationship between BMI and severity 
of CAD and its impact on 1-year mortality in the NL patient population referred for CA at 
a single tertiary care centre.  
2.3 Methods 
2.3.1 Setting 
The health care needs of approximately 528,000 residents [38] of NL, Canada are the 
responsibility of four integrated health authorities. The largest authority, Eastern Health, 
has the only CA laboratory located at the Health Sciences Centre, a tertiary care centre 
which performs all CA referrals from four health authorities. 
2.3.2 Study design and data collection 
Secondary analysis of de-identified data for all adult patients 18 years of age and older 
who had CA between May 1st, 2006 and December 31st, 2013 was conducted using a 
large population-based clinical database. Eastern Health uses a clinical software 
application (i.e., Alberta Provincial Project for Outcome Assessment in Coronary Heart 
Disease [APPROACH]) to prospectively collect detailed demographic, clinical and 
procedural data on all patients referred for CA, undergoing CA procedures, PCI, and 
coronary artery bypass graft (CABG).  Details of the database and methods of collection 
have been previously described. [39]  
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Patients undergoing CA were identified from the cardiac care program’s clinical database. 
There were 21,886 diagnostic CAs performed from May 1st   2006 to December 31st , 
2013. Eligible subjects included all residents of NL over the age of 18 years with a BMI 
≥18.5 kg/m2. The index CA and DJS were used; therefore, duplicate cases (n = 3,369) of 
patients with more than one CA during the observation period were excluded. The 
following patients were also excluded from the  study:  undergone CA during a period of 
time DJS’s were not collected (i.e., 1,871 and 2,750 patients in 2006 and 2007, 
respectively);  all patients who had a procedure performed in 2013 due to the 
unavailability of 1-year mortality data (n = 2,336); missing BMI data (n = 119 or 1.0%) 
or underweight (n = 66 or 0.6%); had history of CABG (n = 776), PCI (n = 749), or 
myocardial infarction (n= 1,538); less than 18 years of age (n = 2); missing DJS data (n = 
110 or 1.2%); missing indication code for CA or if the CA was performed for any reason 
other than the following: acute coronary syndrome, stable angina, unstable angina, 
atypical pain, serious arrhythmia or presenting with cardiovascular symptoms not 
matching the above-mentioned common diagnostic categories. After exclusion criteria 
were applied to the population of patients undergoing CA since the inception of the 
cohort on May 1st 2006, a final study sample of 8,079 patients having a first CA for 
suspected, but not yet confirmed, CAD was identified. 
 
Weight and height were measured and documented by a nurse at the time of CA. If 
patients were unstable, self-reported weight and height were collected and BMI 
calculated. Patients were grouped according to three BMI categories using the World 
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Health Organization classification system: normal (18.5-24.9 kg/m2), overweight (25.0-
29.9 kg/m2), obese class >30 kg/m2. [40] These categorizations reflect relative levels of 
risk to health. [41] It has been demonstrated that obese patients are much more likely to 
die from cardiac causes and lean patients are much more likely to die from non-cardiac 
causes over a 10-year period following index myocardial infarction. [42] In the current 
study, the underweight BMI category (BMI < 18.5	kg/m2) was excluded because of the 
potential impact of comorbid conditions (e.g., advanced heart failure, cachexia) on 
outcome, conditions which are not captured in APPROACH.  
CA data were obtained from the Coronary Artery Reporting and Archiving Tool 
(CARAT), a graphic recording and communication application. [43] Detailed 
angiographic findings of all patients undergoing CA are automatically populated in 
APPROACH and a PDF file is created containing the anatomy of the coronary arteries 
according to the DJS [29] and becomes part of each patient’s medical record. In the 
current study, severity and extent of obstructive CAD is based on the DJS. Dash et al. 
[29] developed the DJS, a prognostic tool predictive of 1-year mortality in patients with 
CAD, which was validated by Califf et al. [30] in 1985. The coronary tree is divided into 
6 segments: the left anterior coronary artery (LAD), diagonal branches of the LAD, septal 
perforating branches, circumflex coronary artery, obtuse marginal branches, and posterior 
descending coronary artery. All segments with ≥75% stenosis, or ≥ 50% left main 
stenosis, are considered to be at risk. Each such segment is assigned 2 points. The 
maximum possible number of points is 12. A score from 0 to 12 is assigned to each CA 
based on the number of segments involved and automatically populated in APPROACH. 
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The usefulness of the DJS as a simple score that is easy to use clinically as a prognostic 
tool has been confirmed in a large Canadian population cohort of > 20,000 patients 
undergoing PCI or CABG. [44] Following PCI, there was no difference between DJSs 0 
and 2; however, a stepwise increase in 1-year mortality with a DJS of >2 was found. 
Mortality data stored in the NL Centre for Health Information (NLCHI) Mortality System 
was provided to Eastern Health’s cardiac care program via a data linkage. The primary 
outcomes of the current study were all-cause and cardiac-specific mortality at 1-year.  
All patients who had a CA during the time period under examination gave written, 
informed consent to the cardiac care program for data collection and follow-up 
observation after CA.  The study protocol received ethical approval from the Health 
Research Ethics Authority of Memorial University and Eastern Health.  
2.3.3 Data analysis  
Analyses are based on 8,079 patients with a BMI ≥ 18.5 kg/m2 undergoing CA for the 
first time. Continuous variables are reported as mean ± standard deviation and were 
compared using ANOVA. Categorical variables are reported as number (%) and were 
compared using chi-square tests. Fisher exact tests were used when the expected number 
was less than 5, if necessary. After the assumptions of survival analysis were met, time-
to-event outcomes were analyzed using Kaplan-Meier survival techniques. The final 
enrollment date was December 31st, 2012 and patients without events were censored on 
December 31st, 2013, the final date for which mortality data was available. Patients who 
died within one year of the procedure were identified and their time to death was 
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determined as the difference between the date of death and date of procedure. Patients 
who did not die within one year were assigned a survival time of 12 months. Survival 
curves were compared using the log-rank test. All factors that could potentially influence 
survival were included (see characteristics in Table 2.1) in addition to BMI and DJS. 
Assumptions of proportionality in Cox regression hazard were tested and met. Univariate 
and multivariate adjusted Cox regression models were performed to identify predictors of 
1-year mortality and compute crude and multivariate-adjusted hazards ratios and 95% 
confidence intervals as a measure of the relative risk of death at one year for increasing 
BMI categories. Normal weight was the referent group (18.5-24.9 kg/m2). Covariates 
included BMI, DJS, age, sex, hypertension, diabetes, hyperlipidemia, smoking history, 
family history of premature CAD, left ventricular (LV) grade, peripheral vascular disease 
(PVD), chronic obstructive pulmonary disease (COPD), renal insufficiency, dialysis, 
chronic renal failure (CRF), congestive heart failure (CHF) and malignancy. A two-sided 
p-value <0.05 was considered statistically significant.  In the model all independent 
variables were dichotomous with the exception of age and BMI. BMI was included both 
as a continuous variable [45] and an ordinal variable. Obesity was defined as a BMI ≥ 30 
kg/m2. All statistical analyses were performed using IBM SPSS Statistics for Windows, 
Version 22.0, Armonk, NY: IBM Corp.  
2.4 Results 
Baseline characteristics are presented in Table 2.1. Among 8,079 patients approximately 
84% were overweight or obese: 1,297 (16.1%) had a normal BMI, 3,072 (38%) had a 
BMI indicating overweight, 3,710 (45.9%) were classified as obese. The average weight 
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in kilograms for the entire sample was 85.2±17.8 and the average BMI was 30.3 ±5.7. 
There were significant differences among BMI categories in terms of age, sex, presence 
of hypertension, diabetes, hyperlipidemia, and family history of cardiovascular disease, 
COPD, PVD and LV grade. Significantly higher proportions of males compared to 
females comprised all BMI categories. As expected, the prevalence of hypertension, 
hyperlipidemia and diabetes significantly increased with increasing BMI. Patients with 
obesity were significantly younger and had a higher rate of a family history of CAD and 
COPD. Normal weight patients had a higher rate of PVD, renal insufficiency, dialysis, 
and LV Grades III and IV. BMI groups did not differ significantly with regards to 
smoking history, CRF, CVD, malignancy, or CHF. A greater proportion of patients with 
angina categorized according to the Canadian Cardiovascular Society as class II-IIII was 
noted in obese; whereas a greater proportion of normal weight patients experienced class 
IV.  
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Table 2.1  
Baseline characteristics of study subjects undergoing coronary angiography in relation to 
BMI category (N= 8079) 
Variable Normal  
 
Overweight 
 
Obese   
 
p-
value* 
Male sex  57.4% 
744/1297  
67.7% 
2081/3072 
60.6% 
2249/3710 
.000 
Weight (kgs ± SD) 64.7±8.8 78.8±9.3 97.7±16.0 .000 
BMI  (mean ± SD) 22.9 ±1.6 27.6±1.4 35.0±4.7 .000 
Age, years 63.4 ± 11.3 62.1 ± 10.6 59.7 ± 10.2 .000 
HTN  56.7%  
735/1297 
60.9% 
1870/3069 
71.0% 
2629/3704 
.000 
Hyperlipidemia  76.4% 
991/1297  
79.3% 
2433/3068 
81.5% 
3022/3706 
.000 
Family history of premature CADǂ 56.4% 
730/1295 
62.8% 
1925/3063 
65.5% 
2421/3695 
.000 
Current/Former Smoker  68.6% 
889/1295 
68.8% 
2105/3060 
 69.2% 
2557/3693  
.890 
Diabetes   15.7% 
203/1297 
 20.8% 
638/3069  
 34.5% 
1279/3708 
.000 
Renal Insufficiency   5.2% 
67/1296 
 4.0% 
124/3069 
 3.5% 
130/3705 
.030 
Dialysis   1.2% 
16/1296 
0.5% 
15/3069 
 0.5% 
19/3705 
.009 
CRF  
 
 2.9% 
38/1296 
 2.2% 
69/3069 
2.0% 
75/3705 
.166 
Malignancy   5.2% 
67/1296 
 4.3% 
132/3069 
 4.1% 
153/3705 
.282 
COPD   16.2% 
210/1297 
 13.0% 
398/3069 
 18.8% 
697/3705 
.000 
PVD   7.0% 
91/1297 
 4.3% 
131/3069 
 3.8% 
139/3705 
.000 
CHF   1.9% 
25/1296 
 1.8% 
54/3069 
 2.2% 
81/3705 
.450 
CVD  6.9% 
90/1296 
 5.3% 
163/3069 
 5.5% 
204/3705 
.088 
CCS Angina Grading Scale 
No angina or atypical symptoms 14.2% 
184/1296 
11.2% 
343/3072	
12.5% 
463/3708	
 
 
 
 
 
 
 
 
.000 
Class 1 2.1% 
27/1296	
2.6% 
80/3072	
2.5% 
94/3708	
Class 2 15.2% 
197/1296 
24.3% 
746/3072 
28.4% 
1053/3708 
Class 3 3.6% 
47/1296 
6.3% 
195/3072 
7.9% 
292/3708 
Class 4 64.9% 
841/1296 
55.6% 
1708/3072 
48.7% 
1806/3708 
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Variable Normal  
 
Overweight 
 
Obese   
 
p-
value* 
LV Grade 
I (>50%)  83.0% 
1067/1286 
 84.3% 
2557/3033 
 86.0% 
3154/3668 
 
 
 
 
 
 
 
 
.003 
II (35-50%)  10.6% 
136/1286 
 11.0% 
334/3033 
 
 9.6% 
353/3668 
 
III (20-34%)  4.0% 
52/1286 
 3.6% 
110/3033 
 
 3.0% 
110/3668 
 
IV (<20%)  2.4% 
31/1286 
 1.1% 
32/3033 
 1.4% 
51/3668 
Values are means ± SD or % (n/N).  
Note. CAD = coronary artery disease; CCS = Canadian Cardiovascular Society; CHF = 
congestive heart failure; COPD = chronic obstructive pulmonary disease; CRF = chronic 
renal failure; CVD = cerebrovascular disease; HTN = hypertension; PVD = peripheral 
vascular disease. 
ǂ Family history of CAD is positive if the patient has/had any direct blood relative 
(parent, siblings, children) who have been diagnosed with angina, MI or sudden cardiac 
death before age 55 years. 
*p value for chi square for categorical variables or ANOVA for continuous variables 
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DJSs calculated during CA by BMI category are presented in Table 2.2. A score of 0, 
indicative of a normal angiogram or non-critical (< 70%) stenosis in any of the coronary 
arteries, was assigned to 526 (40.6%) normal weight patients, 1,197 (39.0%) overweight 
patients, 1,687 (45.5%) obese patients. Differences were observed among BMI categories 
and all DJS levels (p < 0.001), with the exception of DJS ≥ 10. Patients in the obese 
group tended to have lower scores indicating less CAD severity. 
Table 2.2 
Duke Jeopardy Score (DJS) based on coronary angiographic findings in relation to BMI 
category (N= 8079) 
 
Score Normal 
Weight 
(n=1297) 
Overweight 
(n=3072) 
Obese  
(n=3710) 
p value 
≥ 2 771 
(59.4) 
1875 
(61.0) 
2023 
(54.5) 
.000 
≥ 4 542 
(41.8) 
1229 
(40.0) 
1303 
(35.1) 
.000 
≥ 6 424 
(32.7) 
966 
(31.4) 
992 
(26.7) 
.000 
≥ 8 248 
(19.1) 
568 
(18.5) 
593 
(16.0) 
.006 
≥10 162 
(12.5) 
369 
(12.0) 
395 
(10.6) 
.096 
12 91 
(7.0) 
198 
(6.4) 
188 
(5.1) 
.010 
Note. DJS –Duke Jeopardy Score is a score from 0 to 12 which estimates the amount of 
myocardium at risk on the basis of particular location of stenosis. A score of 0 is indicative of a 
normal angiogram or non-critical (< 70%) stenosis in any of the coronary arteries. A score of 0 
was assigned to 526 (40.6%) normal weight patients, 1197 (39.0%) overweight patients, 1687 
(45.5%) obese patients. 
Values are numbers of patients (percentage)  
*p value for chi square for categorical variables 
p <.0.001 for overall difference between groups 
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Within the first year of undergoing CA there were 199 deaths (2.5%) among 8,079 
patients, of which 99 (1.2%) were cardiac-specific.  A significantly higher proportion of 
deaths occurred in patients with normal BMI compared to overweight or obese patients, 
despite more favourable baseline characteristics among the normal weight group (p < 
0.001). There were no statistically significant differences observed for cardiac-specific 
mortality among BMI categories (Figure 2.1a). Mortality tended to rise with incremental 
increases in DJS scores, with the exception of DJS 6 (p < 0.001) (Figure 2.1b). 
 
Figure 2.1a. Unadjusted 1-year all-cause and cardiac-specific mortality according to 
BMI. 
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Figure 2.1b. Unadjusted 1-year all-cause and cardiac-specific mortality according to 
Duke Jeopardy Score. 
 
The unadjusted one-year all-cause survival rates of normal weight, overweight and obese 
groups indicated that survival rates were highest for the obese and overweight groups and 
lowest for the normal weight group (p <0 .001) (Figure 2.2a). There were no significant 
differences among the BMI categories for cardiac-specific mortality (p = 0.106) (Figure 
2.2b).  
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Figure 2.2a (Left). Unadjusted Kaplan Meier and 1-year all-cause mortality in 
patients undergoing coronary angiography by BMI; Figure 2.2b (Right). Unadjusted 
Kaplan Meier and 1-year cardiac-specific mortality in patients undergoing coronary 
angiography by BMI.  
 
The following variables emerged as significant factors associated with 1-year all-cause 
mortality during univariate analyses: age, hypertension, diabetes, family history of 
premature CAD, CHF, PVD, CVD, COPD, malignancy, renal insufficiency, CRF, 
dialysis, DJS and BMI both as a categorical and continuous variable. The variables 
gender and hyperlipidemia were not significant. All statistically and clinically significant 
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variables with p values < 0.20 were included in multivariate Cox proportional regression 
analysis. Multivariate regression analysis showed age, diabetes, PVD, COPD, 
malignancy, renal insufficiency, DJS 8, 10 and 12, LV Grades III and IV as significant 
correlates of 1-year all-cause mortality. BMI was not a statistically significant correlate of 
all-cause mortality; however the hazards ratios and 95% CIs for the overweight (HR, 
0.71; 95%, CI 0.49-1.03) and obese (HR, 0.70; 95% CI, 0.48-1.03) showed a trend toward 
a protective effect when compared to the normal weight category (Table 2.3).  Cox 
regression analysis was also performed using BMI as a continuous variable; however, it 
was not a significant factor associated with 1-year all-cause mortality (data not shown).  
Table 2.3 
Correlates of 1-year all-cause mortality calculated by Cox proportional hazards multiple 
regression analysis  
 Overall 
n=8079 
B S.E. Wald P 
value 
HR 95% CI  
 
Age 61.2 
± 10.6 
.044 .008 26.802 .000 1.04 1.03-1.06 
Hypertension  5234 
(64.9%) 
-.040 .179 .050 .823 .96 .68-1.37 
Diabetes  342  
(36.9%) 
.175 .161 1.18 .277 1.19 .87-1.63 
Family history of premature CAD 5076 
(63.0%) 
-.170 .155 1.19 .274 .84 .62-1.14 
CHF 160  
(2.0%) 
.384 .259 2.193 .139 1.47 .88-2.44 
PVD 361  
(4.5%) 
.517 .223 5.361 .021 1.68 1.08-2.60 
CVD 457  
(5.7%) 
-.041 .232 .032 .859 .96 .61-1.51 
COPD 1305 
(16.2%) 
.585 .166 12.379 .000 1.79 1.29-2.49 
Malignancy 352 
(4.4) 
.559 .238 5.522 .019 1.75 1.10-2.79 
Renal insufficiency 321 
(4.0%) 
.666 .305 4.75 .029 1.95 1.07-3.54 
CRF 182 .355 .375 .898 .343 1.43 0.89-4.28 
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 Overall 
n=8079 
B S.E. Wald P 
value 
HR 95% CI  
 
(2.3) 
Dialysis 50 
(0.6) 
.665 .402 2.738 .098 1.95 0.68-2.97 
Current/former smoker  5551 
(69.0%) 
.196 .174 1.26 .262 1.22 .86-1.71 
DJS        
0 (referent category) 3410 
(42.2%) 
  28.637 .000   
2 1595 
(19.7%) 
-.021 .253 .007 .932 .98 .60-1.61 
4 692  
(8.6%) 
.296 .277 1.14 .286 1.35 .78-2.31 
6 973 
(12.0%) 
-.017 .286 .003 .953 .98 .56-1.72 
8 483  
(6.0%) 
.761 .268 8.088 .004 2.14 1.27-3.62 
10 449  
(5.6%) 
.662 .282 5.501 .019 1.94 1.12-3.37 
12 198  
(6.4%) 
.998 .239 17.415 .000 2.71 1.70-4.33 
LV Grade 
Grade I (Referent 
category) 
6778 
(84.9) 
  50.146 .000   
Grade II 823 
(10.3) 
.309 .216 2.038 .153 1.36 .89-2.08 
Grade III 272 
(3.4) 
1.226 .222 30.423 .000 3.41 2.20-5.27 
Grade IV 114 
(1.4) 
1.568 .280 31.337 .000 4.80 2.77-8.31 
BMI Category 
Normal Weight 1297 
(16.1) 
  4.213 .122   
Overweight 3072 
(38) 
-.341 .189 3.255 .071 .71 .49-1.03 
Obese 3710 
(45.9) 
-.356 .194 3.37 .066 .70 .48-1.02 
Note. BMI = Body mass index; CHF = congestive heart failure; CI= Confidence Interval; COPD 
= chronic obstructive pulmonary disease; CRF = chronic renal failure; CVD = cerebrovascular 
disease; DJS=Duke Jeopardy Score; HR = Hazard ratio; LV = left ventricular; PVD = peripheral 
vascular disease; S.E. indicates standard error. 
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Multivariate regression analysis examining cardiac-specific mortality showed age, CHF, 
DJSs 4 to 12, LV Grades III and IV as significant correlates of 1-year cardiac-specific 
mortality but not BMI (Table 2.4). 
Table 2.4  
Correlates of 1-year cardiac-specific mortality calculated by Cox proportional hazards 
multiple regression analysis 
 Overall 
n=8079 
B S.E. Wald P 
value 
HR 95% CI 
Age 61.2 
± 10.6 
.046 .012 14.646 .000 1.05 1.02-1.07 
Hypertension  5234 
(64.9%) 
.112 .274 .167 .682 1.12 .65-1.91 
Diabetes  342  
(36.9%) 
.312 .225 1.93 .165 1.37 .88-2.12 
Family history of premature CAD 5076 
(63.0%) 
-.098 .222 .196 .658 .91 .59-1.40 
CHF 160  
(2.0%) 
.725 .340 4.56 .033 2.07 1.06-4.02 
PVD 361  
(4.5%) 
.510 .322 2.512 .113 1.67 .89-3.13 
CVD 457  
(5.7%) 
-.027 .329 .007 .935 .97 .51-1.89 
COPD 1305 
(16.2%) 
.275 .247 1.238 .266 1.32 .81-2.14 
Malignancy 352 
(4.4) 
-1.88 1.01 3.491 .062 .15 .02-1.10 
Renal insufficiency 321 
(4.0%) 
.466 .448 1.085 .298 1.59 .66-3.83 
CRF 182 
(2.3) 
.2925 .544 .288 .591 1.34 .46-3.89 
Dialysis 50 
(0.6) 
.422 .636 .440 .507 1.53 .44-5.31 
Current/former smoker  5551 
(69.0%) 
.272 .255 1.14 .286 1.31 .86-1.71 
DJS 
0 (referent category) 3410 
(42.2%) 
  30.545 .000   
2 1595 
(19.7%) 
.242 .436 .307 .579 1.27 .54-3.00 
4 692  
(8.6%) 
1.012 .421 5.763 .016 2.75 1.20-6.28 
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 Overall 
n=8079 
B S.E. Wald P 
value 
HR 95% CI 
6 973 
(12.0%) 
.941 .401 5.513 .019 2.56 1.17-5.62 
8 483  
(6.0%) 
1.46 .407 12.854 .000 4.31 1.94-9.57 
10 449  
(5.6%) 
1.245 .432 8.317 .004 3.47 1.49-8.09 
12 198  
(6.4%) 
1.762 .367 23.023 .000 5.83 2.84-11.99 
LV Grade 
Grade I (Referent 
category) 
6778 
(84.9) 
  37.607 .000   
Grade II 823 
(10.3) 
.239 .320 .559 .455 1.27 .68-2.38 
Grade III 272 
(3.4) 
1.154 .320 12.987 .000 3.17 1.69-5.94 
Grade IV 114 
(1.4) 
1.98 .348 32.352 .000 7.24 3.66-14.33 
BMI Category 
Normal Weight 1297 
(16.1) 
  2.72 .257   
Overweight 3072 
(38) 
-.305 .293 1.083 .298 .74 .42-1.31 
Obese 3710 
(45.9) 
.100 .284 .126 .722 1.11 .64-1.92 
Note. BMI = Body mass index; CHF = congestive heart failure; CI= Confidence Interval; COPD 
= chronic obstructive pulmonary disease; CRF = chronic renal failure; CVD = cerebrovascular 
disease; DJS=Duke Jeopardy Score; HR =Hazard ratio; LV = left ventricular; PVD = peripheral 
vascular disease; S.E. indicates standard error. 
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2.5 Discussion 
Our study examined the relationship between BMI and CAD and 1-year mortality in a 
large cohort of patients undergoing CA for suspected, but not yet confirmed CAD. 84% 
of patients were overweight and obese. It was hypothesized that overweight patients, 
particularly those in the higher BMI categories, would have more severe CAD and be at 
greater risk of death at 1-year compared to normal weight patients. Contrary to our 
hypothesis, we found that normal weight patients had higher unadjusted 1-year all-cause 
mortality than overweight and obese patients despite having more favorable baseline 
characteristics but more severe disease. Obese patients presented with less severe CAD 
based on DJSs despite having a higher prevalence of recognized risk factors including 
hypertension, hyperlipidemia, and diabetes. In the current study, we found differences in 
the average age of obese and non-obese patients, with obese patients being significantly 
younger than their non-obese counterparts. We did not observe a difference in unadjusted 
cardiac-specific mortality across BMI categories.  
In patients with established CAD a reverse J-shaped relationship between all-cause 
mortality and cardiovascular mortality and BMI has been reported in three meta-analyses. 
[19, 20, 46] However, very few studies have examined the association of BMI and CAD 
in patients undergoing CA for suspected, but not yet confirmed CAD. The current study 
findings support the paradoxical findings of Rubinshtein et al. [31] and Niraj et al. [32]. 
In a study by Rubinshtein et al. [31] on 928 patients with CAD, the authors reported an 
inverse relationship between BMI and severity of CAD. Other risk factors such as 
diabetes, hyperlipidemia, and male gender were correlated with severity of CAD. Niraj et 
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al. [32] investigated the relationship between severity of CAD and BMI according to the 
DJS in a sample of 770 patients from the US including 212 Caucasians and 428 African-
Americans. The authors’ also reported a paradoxical relationship. In both studies, the 
obese patients were significantly younger than the normal weight and overweight 
patients, leading to the conclusion that this association could be partly or completely 
explained by the increased likelihood of early physician referral of obese patients for 
cardiac catheterization and therefore at an earlier stage of CAD. The inverse relationship 
between BMI and severity of CAD was also reported most recently by Parsa and 
Jahanshahi [33] in a cross-sectional prospective study performed between September 
2009 and March 2011 among 414 patients with suspected CAD undergoing CA.  
We did not observe a significant relationship between BMI and 1-year all-cause or 
cardiac-specific mortality. After controlling for potential confounders such as other 
cardiovascular risk factors and comorbidities in our analyses, BMI did not emerge as an 
independent factor significantly associated with either all-cause or cardiac-specific 
mortality. The statistically insignificant but clinically relevant odds ratios and confidence 
intervals for both the overweight and obese categories were consistent with a 51% and 
52% reduction in risk of all-cause mortality for overweight and obese patients, 
respectively.  
It is important to note that in the current study, significant proportions of overweight 
(39%) and obese (45.5%) patients who underwent CA did not have CAD based on 
angiographic generated DJSs. We were unable to examine the relationship between BMI 
and mortality in patients who had a CA but were not diagnosed with CAD due to the low 
58	
	
event rates of 45 all-cause and 13 cardiac-specific deaths. In a study conducted by 
Oreopolous et al. [21], the authors reported an obesity paradox in patients who had CA 
with no CAD. The authors offered two explanations for the unexpected finding (1) other 
cardiac risk factors could classify these patients as having “pre-clinical” disease and that a 
higher BMI was protective, and (2) referral and treatment bias in CAD since obesity is a 
“visible” risk factor that may predispose physicians to refer obese patients for CA earlier 
than those with a normal BMI.  Niraj et al. [32] also suggested that the trend of normal or 
minimal change angiography in obese patients in their 2006 study may have been due to a 
tendency of bias of physicians to refer obese patients for earlier angiography. Rubinshtein 
et al. [31] suggested that a younger age could be associated with a lower prevalence of 
high-risk coronary anatomy compared with non-obese older patients. This could partially 
explain the findings of the current study as well. Patients of normal weight were 
significantly older than their obese counterparts and had more angiographic severe CAD 
according to their DJSs. 
Although the mechanism for the potential protective effect of obesity among patients with 
CAD remains unclear, a number of potential mechanisms have been proposed: greater 
metabolic reserves, less cachexia, younger presenting age, more aggressive medical 
therapy, more aggressive diagnostic and revascularization procedures, increased muscle 
mass and strength, possible improved cardiorespiratory fitness despite obesity, 
diminished hormonal response including the renin-angiotensin-aldosterone system, and 
unmeasured confounders, including selection bias. [47]  
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Our study has a number of strengths. We report on a large population-based cohort of 
consecutive patients undergoing CA at a single tertiary cardiac centre using 
APPROACH-NL prospectively collected data. Data quality assurance indicated that the 
amount of missing data was minimal (1.2%). Actual measures of height and weight were 
taken at the time of CA, unless the patients were unstable. We were able to assess the 
effect of BMI on 1-year all-cause and cardiac-specific mortality in patients with and 
without CAD using data linkage to up-to-date mortality data from the NL Vital Statistics 
Division.   
This study also has limitations. First, our study is an observational non-randomized cohort 
study and therefore provides evidence of association not causation. Second, patients with 
missing BMI data were excluded (n = 119), although this accounted for only 1.0%. Third, 
BMI has been criticized as an inaccurate method to investigate body fatness because it is 
not as well correlated to cardiovascular disease and death as other measures of obesity 
including waist circumference and waist-to-hip ratio [47], data that were unavailable in 
the APPROACH clinical database. Fourth, BMI was collected at the time of the index CA 
only and potential changes in BMI were not accessed. Finally subgroups of obese patients 
could not be analyzed due to small numbers. 
2.6 Conclusions 
Obesity was associated with less severe CAD as evidenced by CA, suggesting obese 
patients are more likely to be referred early for CA based on the prevalence of 
cardiovascular risk factors including hypertension, hyperlipidemia and diabetes.  This 
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study failed to detect an association of BMI with 1-year mortality after adjustment for 
potential confounding variables.  
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3.1 Abstract  
 
Background and Aim: Obesity (BMI ≥ 30kg/m2) is associated with advanced 
cardiovascular disease requiring procedures such as percutaneous coronary intervention 
(PCI). Studies report better outcomes in obese patients having these procedures but 
results are conflicting or inconsistent. Newfoundland and Labrador (NL) has the highest 
rate of obesity in Canada.  The aim of the study was to examine the relationship between 
BMI and vascular and non-vascular complications in patients undergoing PCI in NL. 
  
Methods: We studied 6,473 patients identified in the APPROACH-NL database who 
underwent PCI from May 1st 2006 to December 31st 2013. BMI categories included: 
normal, 18.5 ≤ BMI < 25.0 (n=1073); overweight, 25.0 ≤ BMI < 30 (n=2608); and obese, 
BMI ≥ 30.0 (n=2792). 
  
Results: Patients with obesity were younger, had a higher incidence of diabetes, 
hypertension, and family history of cardiac disease. Obese patients experienced less 
vascular complications: (normal, overweight, obese: 8.2%, 7.2%, 5.3%, p =0.001). No 
significant differences were observed for in-lab (4.0%, 3.3%, 3.1%, p =0.386) or post-
procedural (1.0%, 0.8%, 0.9%, p =0.725) non-vascular complications. After adjusting for 
covariates, BMI was not a significant factor associated with adverse outcomes. 
 
Conclusion: Obesity was not an independent correlate of short-term vascular and non-
vascular complications among patients undergoing PCI.	 	
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3.2 Introduction 
Obesity is an independent risk factor for cardiovascular disease [1-5], and is associated 
with advanced cardiovascular disease requiring procedures such as percutaneous coronary 
intervention (PCI) and coronary artery bypass surgery, reduction in life expectancy [6], 
and a higher mortality rate [3,7-8]. A number of observational studies have reported 
improved clinical outcomes (i.e., increased survival benefit) in overweight and obese 
patients treated for cardiovascular diseases compared to normal weight patients, a 
phenomenon commonly referred to as “obesity paradox”. [9-14]  This phenomenon is 
considered to be counter-intuitive, referred to as “reverse epidemiology”, and reported in 
patients with hypertension [15], heart failure [16], coronary artery disease (CAD) [15, 17-
19], coronary artery bypass surgery [17-20], and PCI [17-19]. Inconsistent results have 
been reported regarding the association between BMI and short-term clinical outcomes 
(i.e., vascular complications, non-vascular in-lab and post procedural complications) 
and/or mortality in patients undergoing PCI [9-10,13, 21-27]; therefore, it is not entirely 
clear whether an obesity paradox exists.  
Obesity is a common and rapidly growing public health concern. Between 1985 and 2011 
the prevalence of this disease in Canada increased 200% from 6.1% to 18.3% equating to 
more than 4.8 million adults, with continued increases projected. [28] Newfoundland and 
Labrador (NL) has the highest rate of obesity in Canada. It is estimated that 71% of the 
province’s population will be either overweight or obese by 2019. [28] There is a paucity 
of data on the prevalence of obesity in patients undergoing PCI in the province. 
Furthermore, the relationship between short-term clinical outcomes and BMI has not been 
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examined in patients undergoing PCI in NL.  In the present study, we examine (1) the 
prevalence of obesity among patients undergoing PCI and the differences among BMI 
groups on demographic, clinical and procedural findings, and (2) examine the association 
between the most commonly used anthropometric parameter to assess adiposity (i.e., 
BMI) and short-term outcomes (vascular complications, non-vascular in-lab and post-
procedural complications occurring within 48 hours).  
3.3 Methods 
3.3.1 Study Design 
We performed a retrospective analysis of prospectively collected de-identified data for all 
patients 18 years of age and older who had a PCI between May 1st , 2006 and December 
31st , 2013 in the province of NL, Canada using a well-established clinical database (i.e., 
Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease 
[APPROACH- Newfoundland and Labrador (NL)].  Detailed prospective demographic, 
clinical and procedural data on all patients undergoing diagnostic cardiac catheterization 
and/or percutaneous coronary intervention (PCI) and cardiac surgery since 2006 is 
collected by specifically trained clinical cardiac catheterization database nurses. Nurses 
collect and record on an abstraction sheet patient data provided by nurses responsible for 
the care of the patient which includes examination and assessment of the access site for 
potential vascular complications.  The attending physician also examined the vascular 
access site. All data are verified by chart review until hospital discharge by these nurses.  
Prospectively collected data on each consecutive patient is entered into the APPROACH-
NL clinical database. A research nurse is responsible for the management of the database 
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including completeness of data entry and quality assurance activities. Details of the 
database and methods of collection have been previously described. [29] If patients are 
not hospitalized, they remain in the local area for 24 hours and are advised to return to the 
emergency department (ER) if they encounter any problems. ER admissions are audited 
by a clerk in the cardiac catheterization laboratory in the event a patient returns to the ER.  
3.3.2 Study Population 
For the current study, all consecutive PCIs (N =6633) performed on patients 18 years of 
age and older between May 1st, 2006 and December 31st, 2013 at the Health Science 
Centre, Eastern Health, NL were enrolled. PCI procedures performed on underweight 
(BMI < 18.5kg/m2) individuals (n=47) or those with missing BMI data or unlikely valid 
BMI levels of >70 or <11kg/m2 (n= 113) were excluded. The remaining patients 
comprised the study cohort. Based on these selection criteria, 6,473 patients were 
included in the final analysis.  
 
Weight and height were measured and documented by a nurse at the time of PCI. If 
patients were unstable, self-reported weight and height were collected and BMI 
calculated. Patients were grouped according to three BMI categories using the World 
Health Organization classification system: normal (18.5-24.9 kg/m2), overweight (25.0-
29.9 kg/m2), obese (>30 kg/m2). [30] These categorizations reflect relative increasing 
levels of risk to health. [31]  
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3.3.3 Clinical Outcomes and Definitions 
The primary outcome was short-term complications occurring within 48 hours after the 
intervention. Vascular access complications were defined as hematoma (> 5cm), 
pseudoaneurysm, arteriovenous fistula, vascular occlusion, access site bleeding, 
retroperitoneal bleed, and loss of distal pulse or occlusion. Non-vascular complications 
included in-lab events (abrupt  coronary closure, emergency coronary artery bypass 
surgery (CABG), access site complications, death, ventricular tachycardia/ventricular 
fibrillation, pulmonary edema, shock, and dissection) and post-procedural complications 
(death, myocardial infarction, emergency CABG, abrupt coronary closure, hemorrhagic 
or ischemic CVA, and GI bleed). Each of the outcomes was a composite of the individual 
outcomes defined in each category. 
3.3.4 Ethical Considerations 
All patients who had a PCI during the time period under examination gave written, 
informed consent to the cardiac care program for data collection and follow-up 
observation after PCI.  The study protocol was approved by the Health Research Ethics 
Authority of Memorial University and Eastern Health. 
3.3.5 Data Analysis 
Demographic characteristics, clinical and procedural related variables were summarized. 
Continuous variables were expressed as mean ± standard deviation (SD). Categorical 
variables were expressed as frequencies and percentages. Continuous variables were 
compared using ANOVA, and the differences between categorical variables were 
examined using the χ2 test and, where appropriate, the Fisher exact test is reported. All p 
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values were two-tailed, with statistical significance defined by a p value < 0.05. 
Comparisons were performed for a trend in increasing BMI categories using χ2 test for 
trends. Univariate logistic regression analysis was performed to determine the odds ratio 
for vascular complications and non-vascular complications occurring in the cardiac care 
laboratory identified within 24-48 hours post PCI.  Multivariate logistic regression 
analysis was used to examine independent predictors for each of the patient outcomes. 
Due to the low non-vascular post-procedural complication event rate regression analyses 
were not performed. Variables identified in Tables 3.1 through 3.3 were selected for these 
models based on univariate p values <0.20 and overall clinical significance. All statistical 
analyses were performed using IBM SPSS Statistics for Windows, Version 22.0, 
Armonk, NY: IBM Corp. [32]  
 
3.4 Results 
A cohort of 6,473 patients was identified from the population of patients who had a PCI 
during the time period under examination. BMI for normal weight, overweight and obese 
patients from 2006 to 2013 are presented in Figure 3.1. Tables 3.1 through 3.3 show the 
baseline characteristics of patients according to categories of BMI, medications at time of 
referral, and admitting clinical, angiographic and procedural data. 
Baseline Characteristics 
Of the 6,473 patients 16.6% were normal weight (n= 1073), 40.3% were overweight (n = 
2608) and 43.1% were obese (n=2792). In each of the years examined less than 19% of 
patients who had a PCI were of normal weight (Table 3.1 and Figure 3.1). The baseline 
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characteristics of the study patients according to the three BMI categories are presented in 
Table 3.1. There were statistically significant differences between the groups on a number 
of characteristics. A higher proportion of overweight patients were male. Patients with 
obesity were younger, had a higher incidence of coronary risk factors such as diabetes 
mellitus and hypertension, and had a family history of cardiovascular disease. Patients 
with a higher BMI were also more likely to have COPD, whereas normal weight patients 
were more likely to have PVD. No significant differences were observed in smoking 
status. 
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Table 3.1 Baseline characteristics of patients according to categories of BMI 
Variable Total N NW 
 
OW OB 
 
p 
value* 
Number of patients 6473 1073 2608 2792  
Age, years 6473 65.1 ± 11.1 63.1 ± 
10.5 
60.7 ± 
10.1 
p<.001 
Male sex 6473 695 (64.8) 1975 
(75.7) 
1945 
(69.7) 
p<.001 
Cardiovascular risk factors 
HTN  6462 658(61.4) 1661(63.8) 2066 
(74.1) 
p<.001 
Hyperlipidemia 6462 905 (84.4) 2241 
(86.1) 
2434 
(87.4) 
p= 
.050 
Diabetes 6464 226 (21.1) 637 (24.5) 1040 
(37.3) 
p<.001 
Family history 6440 622 (58.3) 1627 
(62.7) 
1822 
(65.5) 
p<.001 
Smoking status 6421     
Never  1719 298 (28.1) 698 (27.0) 723 
(26.1) 
p= 
.441 
Smoking 
history 
4702 763 (71.9) 1891 
(73.0) 
2048 
(73.9) 
PVD  6460 91 (8.5) 172 (6.6) 156 
(5.6) 
p=.005 
COPD 6459 156 (14.6) 335 (12.9) 479 
(17.2) 
p<.001 
Values are presented as n (%) or mean ± SD, as indicated.  
*p values for chi-squared or ANOVA tests. 
Note. BMI =body mass index; COPD = Chronic obstructive pulmonary disease; NW = 
normal weight; OB = obese; OW = overweight; PCI = percutaneous coronary 
intervention; HTN = hypertension; MI = myocardial infarction; PVD = peripheral 
vascular disease.  
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Figure 3.1.  BMI trends for normal weight, overweight and obese patients who had a 
PCI from 2006 to 2013.  
 
Medications at the time of referral for PCI were examined. The details regarding the use 
of medications prior to PCI are presented in Table 3.2. No significant differences were 
found in the use of acetylsalicylic acid (ASA), warfarin, pre-procedural GP IIb/IIIa 
inhibitors, beta blockers, low molecular weight heparin (LMWH), IV heparin, IV nitrates, 
or statin therapy between the groups. Patients with obesity were less likely to receive a 
thienopyridine antiplatelet medication (ticlopidine/clopidogrel), but were more likely to 
receive an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, calcium 
channel blockers and long acting nitrates. 
Note:	Chi	square	trend	test	p	values	reported	for	BMI	categories.	
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Table 3.2 
Medications at time of referral for PCI by BMI category 
 Total N NW 
 
OW 
 
OB 
 
p value* 
Number of patients 6473 1073 2608 2792  
Beta blockers  6431 863 (81.2) 2154 (83.1) 2318 (83.5) p =.220 
ACE inhibitors 6429 510 (48.0) 1296 (50.0) 1476 (53.2) p =.006 
ARB antagonist  6428 104 (9.8) 305 (11.8) 431 (15.5) p < .001 
CCB  6430 173 (16.3) 433 (16.7) 596 (21.5) p < .001 
LA nitrates 6430 307 (28.9) 729 (28.1) 869 (31.3) p =.032 
Statin therapy  6427 874 (82.3) 2199 (84.9) 2345 (84.5) p =.134 
ASA 6432 983 (92.5) 2402 (92.6) 2612 (94.1) p =.058 
Ticlopidine/Clopidogrel  6432 806 (75.8) 1846 (71.2) 1925 (69.3) p < .001 
Warfarin 6429 15 (1.4) 47 (1.8) 59 (2.1) p =.329 
GP IIb/IIIa inhibitors  6437 5 (0.5) 14 (0.5) 13 (0.5) p =.924 
LMWH  6439 428 (40.2) 971 (37.4) 1003 (36.1) p =.068 
IV heparin  6439 220 (20.6) 497 (19.1) 579 (20.8) p =.268 
IV nitrates  6430 141 (13.3) 313 (12.1) 307 (11.1) p =.149 
Values are presented as n (%). 
*p values for chi-squared tests. 
Note. ACE = angiotensin converting enzyme; ARB = angiotensin receptor blocker; BMI 
=body mass index; CCB = calcium channel blockers; LA nitrates = long-acting nitrates; 
LMWH=low molecular weight heparin; NW = normal weight; OB = obese; OW = 
overweight; PCI = percutaneous coronary intervention. 
 
Angiographic and Procedural Data 
Admitting clinical, angiographic and procedural data are shown in Table 3.3. Normal 
weight patients were significantly less likely to require a closure device (p < 0.001) 
compared to other BMI groups. However, there were no significant differences among the 
BMI categories in the prevalence of prior PCI, prior CABG, prior HF, prior MI, 
pulmonary embolism, thromboembolic history, deep vein thrombosis, same sitting 
angioplasty, intra-aortic balloon pump (IABP) use at time of referral or during the 
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procedure /cardiogenic shock at time of procedure, use of GP IIb/IIIa inhibitors, access 
site, and choice of sheath size. A greater proportion of normal weight patients presented 
as emergency/urgent cases, whereas more elective procedures were performed in 
overweight and obese patients. A greater proportion of obese patients presented with 
unstable angina, whereas a much lower proportion presented with a STEMI. A greater 
proportion of patients with angina categorized according to the Canadian Cardiovascular 
Society as class II-IIII was noted in obese; whereas a greater proportion of normal weight 
patients experienced class IV. 
Table 3.3 
Admitting clinical, angiographic and procedural data for patients undergoing PCI 
according to BMI category 
 
 Total N NW 
  
OW 
 
OB 
 
p value* 
Number of Patients 6473 n= 1073 n = 2608 n = 2792  
Cardiovascular history 
Prior PCI 6462 226 (21.1) 543 (20.9) 627 (22.5) p =.318 
Prior CABG 6462 129 (12.0) 298 (11.5) 289 (10.4) p =.247 
Prior HF 6462 52 (4.9) 83 (3.2) 106 (3.8) p =.052 
Prior MI 6462 212 (19.8) 527 (20.3) 581 (20.8) p =.734 
CVD 6450 89 (8.3) 160 (6.2) 174 (6.3) p =.041 
Same sitting 
angioplasty 
6473 864 (80.5) 2138 (82.0) 2321 (83.1) p =.149 
IABP/Cardiogenic 
shock 
6461 7 (0.7) 16 (0.6) 31 (1.1) p =.104 
Priority 6466  
Low risk 1861 220 (20.5) 783 (30.0) 858 (30.7)  
 
p < .001 
Emergency 397 72 (6.7) 170 (6.5) 155 (5.6) 
Urgent 4208 780 (72.7) 1654 (63.4) 1774 (63.5) 
PE 6216 8 (0.8) 13 (0.5) 15 (0.6) p = .641 
Thromboembolic 
history 
6218 5 (0.5) 12 (0.5) 10 (0.4) p = .797 
DVT 6219 16 (1.6) 32 (1.3) 32 (1.2) p = .663 
CCS Angina Grading 
Scale 
6469 1071 2606 2791  
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No pain or atypical 
symptoms 
 69 (6.4) 123 (4.7) 128 (4.6)  
 
 
 
 
p < .001 
Class 1  11(1.0) 43 (1.7) 35 (1.3) 
Class 2  108 (10.1) 434 (16.7) 463 (16.6) 
Class 3  90 (8.4) 270 (10.4) 326 (11.7) 
Class 4  794 (74.1) 1736 (66.6) 1839(65.9) 
Stable angina 1748 202 (18.9) 731 (28.1) 815 (29.3) p < .001 
ACS 4341 n=791 n=1724 n=1825  
 
 
 
 
 
p = .001 
STEMI
  
1227 251 (31.7) 501 (29.1) 475 (26.0) 
Non-
STEMI 
1939 349 (44.1) 787 (45.6) 803 (44.0) 
Unstable 
angina  
1174 191 (24.1) 436 (25.3) 547 (30.0) 
Thrombolytics 
contraindicated  
4143 11  (1.5) 27 (1.6) 24 (1.4) p = .831 
Failed 
thrombolysis 
4274 26  (3.4) 77 (4.5) 59 (3.3) p =.122 
Access site 
Radial/Brachial 1172 193(18.0) 468(17.9) 511(18.3)  
p=.938 Femoral 5301 880 (82.0) 2140 (82.1) 2282 (81.7) 
Sheath size 
     Sheath size 5 Fr 924 160 (14.9) 393 (15.1) 371 (13.3)  
 
p =.386 
     Sheath size 6 Fr 5432 893 (83.2) 2171 (83.3) 2368 (84.9) 
     Sheath size 7/8 Fr 114 20 (1.9) 43 (1.6) 51 (1.8) 
Closure device 6470 484 (45.1) 1359 (52.1) 1506 (54.0) p < .001 
GP IIb/IIIa inhibitors 6471 134 (12.5) 338 (13.0) 351 (12.6) p =.889 
Values are presented as n (%). 
*p values for chi-squared tests. 
Note. BMI =body mass index; CABG = coronary artery bypass grafting; CCS = Canadian 
Cardiovascular Society; CVD = cerebrovascular disease; HF = heart failure; IABP = 
intra-aortic balloon pump; MI = myocardial infarction; NW = normal weight; OB = 
obese; OW = Overweight; PCI = percutaneous coronary intervention; PE = pulmonary 
embolism; PVD = peripheral vascular disease; STEMI = ST elevation myocardial 
infarction. 
  
Complications occurring with 24 to 48 hours of PCI according to BMI   
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Complications occurring with 24 to 48 hours of PCI according to BMI category are 
presented in Table 3.4 and Figure 2.2. Obese subjects experienced a lower proportion of 
vascular complications: (normal, overweight, obese: 8.2%, 7.2%, 5.3%, p = 0.001). No 
significant differences were observed for non-vascular complications either in-lab (4.0%, 
3.3%, 3.1%, p =0.386) or post-procedural (1.0%, 0.8%, 0.9%, p =0.725).  
Table 3.4 
Vascular and non-vascular complications occurring within 24 to 48 hours in patients 
undergoing PCI according to BMI category 
 
 NW 
(n=1073) 
OW 
(n =2608) 
OB 
(n =2792) 
p 
value* 
Vascular complications 88 (8.2) 187 (7.2) 149 (5.3) 0.001 
Non-vascular in-lab complications 43 (4.0) 87 (3.3) 87 (3.1) 0.386 
Non-vascular post-procedural  
complications 
11 (1.0) 20 (0.8) 25 (0.9) 0.725 
Values are presented as n (%). 
Note. BMI = body mass index; NW = Normal Weight; OW = Overweight; OB = Obese; 
PCI= percutaneous coronary intervention 
*p values for chi-squared tests. 
Vascular complications were defined as hematoma (> 5cm), pseudoaneurysm, 
arteriovenous fistula, vascular occlusion, access site bleeding, retroperitoneal bleed, loss 
of distal pulse or occlusion.  
Non-vascular complications occurring in-lab included abrupt coronary closure, 
emergency coronary artery bypass surgery (CABG), access site complications, death, 
ventricular tachycardia/ventricular fibrillation, pulmonary edema, shock, and dissection.  
Non-vascular post-procedural complications included death, myocardial infarction, 
emergency CABG, abrupt coronary closure, hemorrhagic or ischemic CVA, and GI 
bleed. 
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Figure 3.2.  Prevalence of vascular and non-vascular complications (in-lab and post-
procedural) by BMI category. 
 
We performed multivariate analyses to adjust for clinical and procedural characteristics. 
Independent factors associated with the primary outcomes of vascular complications and 
non-vascular in-lab complications are shown in Tables 3.5 and 3.6. Increasing age, GP 
IIb/IIIa inhibitor and LMWH use during the procedure, and the utilization of a femoral 
access site approach were significant factors associated with the occurrence of vascular 
complications. Males, patients with diabetes and patients who had a closure device, and 
PCIs performed in 2010 were less likely to have vascular complications. GI/liver disease, 
warfarin use, utilization of GP IIb/IIIa inhibitors or IV Heparin during PCI, and older age 
were significant factors associated with the occurrence of non-vascular in-lab 
complications. Male sex and the use of a closure device were protective factors associated 
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with a less likelihood of non-vascular in-lab complications. BMI was not a significant 
factor associated with either vascular or non-vascular in-lab complications (Tables 3.5 
and 3.6). 
Table 3.5 
Multivariate adjusted OR for vascular complications in patients undergoing PCI 
 OR 95% CI p value 
Age 1.02 1.01-1.03 0.001 
Male 0.69 0.55-0.86 0.001 
Diabetes 0.65 0.51-0.84 0.001 
Sheath size 5Fr  0.42 0.20-0.85 0.016 
Procedural GP 
IIb/IIIa inhibitors 
1.95 1.50-2.54 0.000 
Pre-procedural 
LMWH 
1.29 1.03-1.61 0.029 
Closure device 0.54 0.43-0.68 0.000 
Femoral Access 2.98 2.00-4.45 0.000 
Year, 2010 0.49 0.30-0.80 0.005 
BMI (Referent category is normal weight) 
Overweight 1.01 0.76-1.33 .967 
Obese 0.83 0.62-1.11 .219 
 
Adjusted for access site, age, ASA, BMI, closure device, diabetes, gender, GI/liver 
disease, LMWH in-lab, LMWH pre-procedural, GP IIb/IIIa inhibitors in-lab, GP IIb/IIIa 
inhibitors pre-procedural, pre-procedural IV Heparin, prior CVD, prior HF, prior PCI, 
sheath size, smoking status, Ticlopidine/Clopidogrel, year. 
Note. BMI =body mass index; CVD = cardiovascular disease; GP = glycoprotein; HF = 
heart failure; LMWH=low molecular weight heparin; PCI = percutaneous coronary 
intervention. 
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Table 3.6  
Multivariate adjusted OR for non-vascular in-lab complications in patients undergoing 
PCI 
 
 OR 95% CI P value 
Age 1.02 1.001-1.03 0.039 
Male 0.64 0.47-0.87 0.005 
GI/Liver disease 1.53 1.02-2.27 0.038 
GP IIb/IIIa 
inhibitors in-lab 
4.99 3.65-6.81 0.000 
IV Heparin in-lab 1.70 1.14-2.52 0.009 
Warfarin 2.38 1.14-4.98 0.021 
Closure Device 0.28 0.19-.040 0.000 
BMI (Referent category is normal weight) 
Overweight 0.93 0.62-1.38 0.705 
Obese 0.54 0.58-1.32 0.879 
 
Adjusted for age, BMI, closure device, diabetes, dvt, family history of premature CAD, 
GP IIb/IIIa inhibitors in-lab, gender, GI/liver disease, hypertension, IV Heparin in-lab, 
LMWH in-lab, prior CABG, prior COPD, prior CVD, prior HF, prior PCI, prior PVD, 
pulmonary embolism, sheath size, warfarin, year. 
Note. BMI =body mass index; CAD = coronary artery disease; CABG = coronary artery 
bypass surgery; COPD = chronic obstructive pulmonary disease; CVD = cardiovascular 
disease; DVT = deep vein thrombosis; GP = glycoprotein; HF = heart failure; 
LMWH=low molecular weight heparin; PCI = percutaneous coronary intervention; PVD 
= peripheral vascular disease.  
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3.5 Discussion 
The present study examined all adult patients who had a PCI procedure performed 
between 2006 and 2013 in one Canadian province to determine the prevalence of obesity 
in this patient population and trend in rates over time. A second objective was to examine 
the relationship between BMI and short-term vascular and non-vascular complications 
occurring within 48 hours and compare outcomes among three BMI categories (normal 
weight, overweight and obese). The majority of patients (84.3%) were either overweight 
or obese. Our study findings are comparable to other studies that have used PCI registries. 
[10-11, 26] In the current study we found that over time there was a significant trend of 
decreasing prevalence for the normal weight category of patients undergoing PCI (p = 
0.048). Similar to previous studies, the current study demonstrates that obese patients 
presented with more risk factors for CAD than overweight or normal weight patients. 
Obese patients were younger, diabetic, and hypertensive and had higher rates of 
hyperlipidemia and family history of CAD. 
We hypothesized BMI was an independent correlate of outcome in patients undergoing 
PCI, more specifically, obese patients would experience worse outcomes compared to 
normal and overweight patients. The obese patients in the present study were significantly 
younger and had higher incidence of coronary risk factors such as diabetes mellitus and 
hypertension, and had a family history of cardiovascular disease, but based on the 
findings of the univariate analyses had a significantly lower rate of vascular 
complications (hematoma (> 5cm), pseudoaneurysm, arteriovenous fistula, vascular 
occlusion, access site bleeding, retroperitoneal bleed, loss of distal pulse or occlusion) 
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than their normal weight and overweight counterparts. There were no significant 
differences in the rates of nonvascular in-lab (acute coronary closure, emergency CABG, 
access site complications, death, ventricular tachycardia/ventricular fibrillation, 
pulmonary edema, shock, and dissection) and post procedural complications (death, 
myocardial infarction, emergency CABG, abrupt coronary closure, hemorrhagic or 
ischemic CVA, and GI bleed) among the BMI categories.  
After multiple logistic regression analysis, BMI was not a significant predictor of short-
term outcomes (vascular complications or in-lab non-vascular complications). Our data 
regarding BMI in NL patients is consistent with one previous Canadian study, but is 
contradictory to the findings of a 2009 study conducted by Byrne et al [24]. Similar to our 
findings, Shubair et al [10] evaluated the effect of BMI on in-hospital outcomes in a 
consecutive series of coronary artery disease patients undergoing PCI enrolled in a 
clinical database at the Hamilton Health Sciences in Ontario Canada. The authors found 
that obesity was not associated with in-hospital post-procedural death, myocardial 
infarction, repeat PCI, CABG, or major adverse cardiac event defined as a composite of 
death, myocardial infarction, repeat PCI, and CABG. Using a large Canadian provincial 
registry, Byrne et al [24] investigated the relationship between BMI, bleeding, and 
outcome (i.e., 1- year mortality) after PCI.  The authors reported that lower BMI (≤ 18.5 
kg/m2) and higher BMI (≥ 40 kg/m2) patients were at greater risk of bleeding and death 
after PCI. Other studies conducted in Western society have reported underweight [9, 21, 
24], normal weight [9, 21] and extremely obese patients [25-27] are at greater risk for 
adverse outcomes after PCI. Cox et al [9] reported that the rate of vascular complications 
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was highest in extremely thin and morbidly obese patients and lowest in moderately 
obese patients. In a study by Gruberg et al [21], the authors reported normal weight 
patients were at the highest risk for in-hospital complications (i.e., major bleeding, 
vascular complications, emergency CABG, and myocardial infarction) and cardiac death 
compared to overweight and obese patients. Two studies by Gurm et al. [22-23] 
suggested that being moderately obese conferred a protective effect, referred to as an 
“obesity paradox”, in relation to vascular complications and major adverse outcomes after 
PCI, a finding consistent with that reported by Cox et al. [9]  
In other studies that have focused primarily on the comparison of normal weight and 
extremely obese (≥ 40 kg/m2) patients undergoing PCI, researchers have reported that 
extremely obese patients have increased vascular complications [26] compared to normal 
weight individuals and higher rates of in-hospital mortality [25-27] compared to 
overweight individuals. In the current study, we were unable to examine the various 
classes of obesity due to the small numbers in each category.  
Our study has a number of strengths. We report on a large population-based cohort of 
patients undergoing PCI at a single tertiary cardiac centre using APPROACH-NL 
prospectively collected data. Data quality assurance indicated that the amount of missing 
data was minimal (1.7%). Actual measures of height and weight were taken at the time of 
the procedure unless the patients were unstable. 
This study also has a number of limitations. Our study is an observational non-
randomized cohort study with retrospective analysis. The current study design can only 
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establish association and not causation.  We used data from a clinical database and as 
such cannot account for confounders not captured in the database. The study population 
was heterogeneous (i.e., included patients with variable levels of coronary artery disease 
severity ranging from acute coronary syndrome with cardiogenic shock to stable angina). 
Patients with missing BMI data were excluded (n = 113) which may contribute to 
selection bias, but as missing data only accounted for 1.7%  this is unlikely. Despite its 
widespread use, the use of BMI in terms of its accuracy to define obesity is controversial. 
[33-35] BMI is not as well correlated to cardiovascular disease and death as other 
measures including waist circumference and waist-to-hip ratio [36], data that were 
unavailable in the clinical database.  A lack of underweight and severely obese patients 
meant that comparisons in our study were made between only three BMI groups: normal 
weight, overweight, and obese.  
3.6 Conclusion 
Obesity was not an independent predictor of short-term outcomes (vascular or non-
vascular complications occurring within 24 to 48 hours) in patients undergoing PCI at our 
institution. 
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Chapter 4 Summary 
This program of research was designed to investigate associations between BMI and 
clinical outcomes in patients with suspected as well as documented CAD. This final 
chapter provides a summary discussion of the findings, the strengths and limitations of 
the studies, the clinical implications of the findings, plans for knowledge translation, 
identification of future research, and conclusions of this study. The first section includes a 
summary of the findings. The second section provides a description and discussion of the 
strengths and limitations of the studies. The third section outlines the clinical implications 
and knowledge translation. Topics within this section include knowledge translation of 
the findings arising from this research to date and planned translational activities. The 
fourth section describes potential areas for future research in this area. The final section 
includes a summary of the conclusions of this research. 
4.1 Summary of the Current Research Findings 
This research contributes new evidence from Canada to the debate surrounding the 
associations between BMI and clinical outcomes in patients with suspected as well as 
documented CAD. Despite the known adverse effects of obesity on the development, 
severity and progression of CAD, a number of studies have provided evidence of the 
existence of an “overweight paradox” and/or an “obesity paradox” after CA and/or  PCI; 
while, fewer studies have not provided support for this phenomenon. Our findings 
contradict the findings of the majority of studies that have investigated this issue and 
suggested that a protective effect on clinical outcomes exists in overweight and/or obese 
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individuals. Our findings are consistent with the findings reported by several researchers 
who found no evidence of an obesity paradox after PCI. [1-5]  
The first paper in Chapter 2 focused on the relationship between BMI and severity of 
CAD in patients referred for and undergoing diagnostic CA for suspected CAD in NL, 
Canada. The primary outcome of the research was 1-year all-cause and cardiac-specific 
mortality. This study failed to detect an association of BMI with 1-year mortality after 
adjustment for potential confounding variables. The findings did suggest that obesity was 
associated with less severe CAD as evidenced by CA, suggesting obese patients are 
potentially more likely to be referred early for CA based on the prevalence of 
cardiovascular risk factors including hypertension, hyperlipidemia and diabetes.  Previous 
studies have suggested that the presence of comorbid conditions in obese and overweight 
younger patients usually leads to more aggressive therapy of cardiovascular risk factors 
which likely leads to improve outcomes despite obesity. [4-9] For example, in a study of 
130,139 patients hospitalized for CAD, higher BMI was associated with increased use of 
standard medical therapies such as ASA, beta-blockers, renin-angiotensin inhibitors, and 
lipid lowering therapy and increased likelihood of undergoing CA and revascularization. 
[7-8] Younger age may also be associated with lower CAD burden with a lower 
prevalence of high-risk coronary anatomy compared with non-obese patients. [8-10] 
Despite this it has been reported that obese patients undergo more diagnostic and 
revascularization procedures than patients with low or normal weight. [4] 
The second paper in Chapter 3 focused on the relationship between BMI and short-term 
adverse events including vascular and non-vascular (i.e., in-lab and post-procedural) 
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complications in patients with established coronary artery disease who were undergoing 
PCI. The findings suggested that obesity was not an independent predictor of short-term 
outcomes (vascular or non-vascular complications occurring within 24 to 48 hours) in 
patients undergoing PCI at our institution. Similar findings have been reported by others 
[2, 4, 11] but are in contrast with previous reports showing more positive clinical 
outcomes in overweight and/or obese patients [12-17]. 
It has been proposed that the apparent paradox that has been observed by other 
researchers may be the result of collider stratification, a source of selection bias that is 
common in epidemiology research. [18] According to Banack and Kaufman [19] the 
typical demonstration of this bias results from conditioning on a variable affected by 
exposure with the outcome (referred to as a collider). Distortion of the association 
between exposure and outcome as a result of this conditioning on a collider can therefore 
produce a spurious protective association between obesity and mortality in disease 
groups. [19] 
Other potential mechanisms through which an obesity paradox could arise have been 
offered including greater metabolic reserves, less cachexia, younger presenting age, more 
aggressive medical therapy, more aggressive diagnostic and revascularization procedures, 
increased muscle mass and strength, possible improved cardiorespiratory fitness despite 
obesity, attenuated hormonal response including renin-angiotensin-aldosterone system, 
unmeasured confounders, including selection bias. [20] Other researchers have 
specifically addressed the issue of bias and the obesity paradox proposing that the obesity 
paradox may be associated with biases such as lead time bias, confounding bias, and 
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publication bias [21], biases that cannot be completely corrected for by statistical means 
[3]. Lead time bias occurs when early detection of the disease is confused with prolonged 
survival. Obese individuals have an increased pre-test probability for CHD which could 
lead to earlier testing, and early diagnosis could result in increased survival. In contrast, 
lean individuals have a lower pretest probability, and consequently present with more 
advanced disease, and thus a worse subsequent prognosis. The authors also suggest that 
there is a potential for confounding bias, for example, smoking and lower BMI have been 
associated with mortality. The authors also suggest that the findings of decreased survival 
among obese individuals might not be considered new research resulting in negative 
studies being less likely to be published than positive studies resulting in publication bias. 
[21]  
4.2 Strengths and Limitations 
This study has both strengths and limitations. Selection bias was limited with the use of a 
large population-based cohort of patients undergoing diagnostic cardiac catheterization 
and PCI at a single tertiary cardiac centre using APPROACH-NL prospectively collected 
data. Data quality assurance indicated that the amount of missing data was minimal 
(1.7%). Actual measures of height and weight were taken at the time of the procedure 
unless the patients were unstable. 
This study also has a number of limitations mostly linked to the retrospective nature of 
the analysis and to the lack of ability to adjust for confounding variables. The design of 
the study was an observational non-randomized cohort study with retrospective analysis. 
Therefore, only association and not causation can be established. In an attempt to adjust 
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for a large number of risk factors (i.e., potential confounders) and a small number of 
events per variable, we summarized covariate information into a propensity score for 
inclusion in the outcome model; however, this analytical method was not feasible. Data 
from a clinical database was used and as such cannot account for confounders not 
captured in the database. The study population was heterogeneous (i.e., included patients 
with variable levels of coronary artery disease severity ranging from acute coronary 
syndrome with cardiogenic shock to stable angina).  
Patients with missing BMI data were excluded (n = 113) which may contribute to 
selection bias, but as missing data only accounted for 1.7%  this is unlikely. Despite its 
widespread use, the use of BMI in terms of its accuracy to define obesity is controversial 
given its inability to differentiate lean mass and body fat. [21-24] BMI is not as well 
correlated to cardiovascular disease and death as other measures including waist 
circumference and waist-to-hip ratio [21], data that were unavailable in the clinical 
database.  It is well documented that respondents have a tendency to underestimate their 
weight and/or overestimate their height. [25] However, self-reported height and weight 
are considered valid for identifying relationships in epidemiologic studies [26], with self-
reported values being strongly correlated with measured values [27-28]. This research 
examined BMI at an initial point in time and related it to mortality a 1-year. A lack of 
underweight and severely obese patients meant that comparisons were limited to three 
BMI groups: normal weight, overweight, and obese. A number of researchers had 
reported that severely obese (BMI ≥40 kg/m2) individuals have more vascular 
complications compared to normal weight individuals and higher rates of in-hospital 
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mortality [29-31]; however, the relatively small sample size for patients in the extreme 
ends of BMI classification limited the statistical power and did not yield an adequate 
number of observations for multivariate regression analyses of infrequent adverse events. 
4.3 Clinical Implications and Knowledge Translation 
The clinical implications of whether or not obesity is directly associated with adverse 
outcomes such as 1-year mortality in patients referred for CA for suspected CAD is still 
subject to debate. This is also the case for patients undergoing PCI as a treatment option 
for CAD.  Referral bias may partially explain the finding of the absence of significant 
CAD in obese patients in the current research. Obese and overweight patients may have 
been referred for cardiac catheterization at an earlier stage of coronary involvement. 
Patients may have experienced more severe symptoms (e.g., chest pain, shortness of 
breath, increased blood pressure) or disability suggestive of symptomatic CAD leading to 
an increased likelihood of referral for CA.  
Knowledge Translation 
The results of this study have been presented locally and internationally. Research 
findings were disseminated on a local level via oral presentations at the Resident 
Research Days in the years 2014 through 2016. Finally, this research was disseminated at 
the international level at The Obesity Society - Obesity 2015 - Annual Scientific Meeting 
in Los Angeles, California.  
Two manuscripts were prepared and submitted for publication. The first manuscript has 
been published in the journal Cardiology Research and Practice. The second manuscript 
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arising from this research has been submitted for peer review to the Journal of the 
American Medical Association Cardiology. Planned future translational activities include 
presentations at the Clinical Epidemiology Seminar Series, Memorial University and to 
the Cardiac Care Program at Eastern Health.  
4.4 Future research  
The findings of the current research indicate that obesity and overweight were not 
associated with worse short-term outcome in patients undergoing CA or PCI. These are 
invasive procedures with inherent risk associated with each. Determining the accuracy of 
referral patterns for cardiac catheterization was beyond the scope of the current research 
but given the findings of less severe disease in the obese and overweight classes of BMI, 
future clinical investigation focusing on referral patterns may be worthwhile. In addition, 
prospective evaluation of obesity as a risk factor for adverse events after PCI requires 
data from multiple cardiac centres in order to provide satisfactory power to detect 
increased risk for infrequent adverse events among all BMI groups.  Finally, it has been 
suggested that future analyses should correct for survivor selection with probabilistic bias 
analysis techniques or inverse probability-of-censoring weights. [19] 
4.5  Conclusions 
In summary, the findings of the current research did not support the existence of either an 
overweight or obesity paradox.  BMI was not associated with increased mortality and 
severity of CAD in patients referred for suspected CAD or with short-term clinical 
outcomes following PCI. It is important to emphasize that despite the negative findings 
associated with the two current studies, obesity is an independent risk factor of advanced 
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cardiovascular disease and mortality. An overweight or obesity paradox may indeed exist 
but physicians should be aware that patients with an increased BMI remain at high risk 
for the development of CAD and poor outcomes over the long-term. [6] 
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